Alicia Jenkins 1

CURRICULUM VITAE

ALICIA J. JENKINS

March 2014

Alicia Jenkins 2

Index

Page

Executive Summary 3 Personal Details / Contacts 4 Education / Qualifications 5 Hospital and Academic Appointments 6 Honours 7 Memberships 8 Review Duties 10 Collaborations 12 Grant funding 14 Student and Post-Doctoral Fellow Supervision 23 Hosted Academic Visitors 30 University Committees / Conference Organization 30 Clinical Teaching 31 Invited Lectures 32 Publications 40 Drug and Device trials 59 Advisory Boards 60 Community Activities 61

Alicia Jenkins 3

EXECUTIVE SUMMARY Alicia Jenkins has recently joined the Faculty of Medicine at The University of Sydney as a Professor of Diabetes and Vascular Medicine. She is a clinical endocrinologist and lipidologist, focusing on Type 1 and Type 2 diabetes and their associated microvascular and macrovascular complications. She has a high profile nationally and internationally for her research into the prediction and prevention and underlying mechanisms of diabetes complications and in the use of frontier technologies in diabetes care, including insulin pumps, continuous glucose monitors and telehealth. With over 25 years of research experience she leads both clinical and basic science research groups exploring diabetes and it complications, pre-diabetes, beta cell biology, circulating and tissue biomarkers, vascular imaging and telehealth. She has extensive research collaborations locally and globally. She is unique in having skills in basic sciences (cell and molecular biology [including genetics, epigenetics and the gut microbiome] and animal models), clinical medicine, clinical trials research and translation of evidence in to practice in the specialty areas of adult and paediatric diabetes, lipids, biomarkers and cardiovascular disease. She is sought after as a lecturer to her peers and to lay communities in Australia and overseas. Her clinical practice relates predominantly to Type 1 diabetes care from youth to old age, including insulin pump and glucose sensor use.

She is a strong teacher, leader, and collaborator. She mentors numerous undergraduate and post-graduate clinicians and scientists, and has supervised to completion one Fulbright Scholar, six PhDs, two MDs, and 12 Honours and BMedSci graduates in the last 12 years. She has eight ongoing PhD candidates. She has an outstanding publication track record, with over 200 published articles, including over 160 peer-reviewed original research articles in leading journals in her field, as well as numerous highly-cited reviews and book chapters, and a major international textbook in lipoproteins in diabetes (Humana-Springer press Diabetes series) as the Chief Editor. She sits on a number of Committees forming guidelines and Position Statements for Clinical Practice in Australia, including those under the auspices of NHMRC, the Australian Diabetes Society (ADS), and Diabetes Australia, and recently completed 8-years on the ADS Council. She is also a long-standing Board member of Insulin for Life (IFL), and a member of the Steering Committee of the International Diabetes Federation “Life for a Child” Program. Professor Jenkins and her colleagues have been awarded over $55 million of funding for medical research. For the last 13 years she has led a multidisciplinary team in Australia and also continued collaborative research in the USA and in EU, undertaking clinical and basic science research related to diabetes and its vascular complications and the use of diabetes technologies, including telemedicine. She leads a well-equipped group with expertise in clinical, biochemical and genetic and epigenetic markers of relevance to diabetes and its complications, obesity, and cardiovascular disease. The team is skilled in several hundred assays, which they validate, utilize and make available to national and international collaborators. She currently holds two patents related to treatments for diabetes complications. Her telehealth initiatives include Type 1 and Type 2 diabetes care, retinal screening and cardiovascular care in Indigenous Australians, and obesity management. Alicia’s research and clinical knowledge have impacted clinical practice: examples include the NHMRC standards of Type 1 diabetes care, insulin pump guidelines and patient-centred decision support algorithms for glucose sensor augmented insulin pump use, national lipid and glucose control guidelines in diabetes care, an understanding of the mechanisms of action of novel therapies to prevent diabetic microvascular complications. Her public good work has led the growth of the international IFL program for access to insulin and related diabetes supplies that have eased and saved the lives of many people with diabetes in over 45 disadvantaged countries. Her overall future goals include to improve clinical outcomes for people around the world with or at high risk of diabetes and its complications through a better understanding of the mechanisms of tissue damage and protection, better treatment algorithms, novel therapeutics, the use of telehealth for screening and care provision and equitable access to healthcare.

Alicia Jenkins 4

CONTACT DETAILS

Work address Sydney University of Sydney NHMRC Clinical Trials Centre Level 6 92-94 Parramatta Rd Camperdown, 2050 NSW Australia Phone +61 2 80365210 Fax +61 2 95651863 Mobile + 61 407229375 Email : alicia.jenkins@ctc.usyd.edu.au

Alicia Jenkins 5

EDUCATION: 1971-1976 Sacred Heart College, Shepparton, Australia 1977 - 1983 University of Melbourne, Faculty of Medicine 1987 Royal College of Physicians (United Kingdom) 1988 - 1994 Royal Australasian College of Physicians Advanced Training in Endocrinology 1989 - 1991 University of Melbourne, Faculty of Medicine Doctorate in Medicine (MD). DEGREES: MBBS University of Melbourne. 1983. MRCP Royal College of Physicians (United Kingdom). 1987. MD University of Melbourne. 1993. Thesis: Lipids in Diabetes Mellitus FRACP Royal Australasian College of Physicians. (no 6463) 1994. Accredited in General Internal Medicine and Endocrinology. FRCP (Edinburgh) Royal College of Physicians (Edinburgh). 2001. MEDICAL LICENSURE: 1984 - present. Australia - State of Victoria. Registration no: MPG200447 and Medical

Board of Australia Medical Practitioners Medical Defence Insurance: MIPS membership #89233 1987 - present General Medical Council (UK). On Overseas List since 1988. 1991 - present Irish Medical Council. On Overseas List since 1992. 1998 USMLE Steps I, II, and English exam (USA). POST-GRADUATE HOSPITAL APPOINTMENTS: Jan. 1984 - Feb. 1985 Intern, St. Vincent’s, Melbourne, Australia.

Rotations in General Medicine, General Surgery, Accident and Emergency, Pediatrics, and Anaesthetics.

Alicia Jenkins 6

Feb. 1985 - Feb. 1986 Junior Resident Medical Officer. St. Vincent’s, Melbourne, Australia. Rotations in General Medicine, Endocrinology, Rheumatology and Rehabilitation, Neurology, Intensive Care, Accident and Emergency.

Feb. 1986 - Feb. 1987 Senior Resident Medical Officer. St. Vincent’s, Melbourne, Australia.

Rotations in General Medicine, Endocrinology, Haematology, Rheumatology and Rehabilitation, Intensive Care, Accident and Emergency, Dermatology, Geriatrics.

June - Oct. 1987 Medical Registrar, Drs. Seaton and Noble, Royal Infirmary Edinburgh,

Scotland. Rotation in General Medicine and Cardiology, Oct. - Nov. 1987 Medical Registrar, Dr Peter Mustchin, Cumberland Infirmary, Carlisle,

England. Rotation in General Medicine, including Cardiology and Intensive Care.

Feb.1988 - Feb. 1989 Endocrinology Registrar, Dr Alford, St.Vincent’s, Melbourne, Australia. Feb 1989 - June 1991 Clinical Associate, Endocrinology Unit, St.Vincent's, Melbourne,

Australia. After-hours Registrar in General Medicine, and Accident and Emergency.

June 1991 - July1992 Senior General Medical and Endocrine Registrar, Professor Gerald Tomkin Adelaide Hospital, Dublin, Ireland. Aug 1992 - June 1993 Registrar in Respiratory Medicine, Clinical Chemistry, and Accident and

Emergency. St.Vincent’s, Melbourne, Australia Dec.1992 - June 1993 Research Fellow (Diabetes), St. Vincent's, Melbourne, Australia.

Associate Professor James Best. Lecturer in Medicine, Monash University, Melbourne, Australia. Professor Mark Wahlquist

March 2000-08 Physician to and Head of St Vincent’s Lipid and Vascular Disease Risk Factor Clinic, Melbourne, Australia

March 2000 - Physician to St Vincent’s Young Adult’s Diabetes Clinic, Melbourne,

Australia January 2002 – 12 Physician to Royal Children’s Hospital Diabetes Clinic, Melbourne, Australia FACULTY APPOINTMENTS : Feb. 1989 - June 1991 Clinical Instructor, University of Melbourne, Australia June 1991 - July 1992 Lecturer in Medicine, Trinity College Dublin, Ireland and Tutor in Medicine, Adelaide Hospital, Dublin, Ireland

Alicia Jenkins 7

Dec. 1992 - June 1993 Lecturer in Medicine, Monash University, Melbourne, Australia and Research Fellow, St. Vincent’s, Melbourne, Australia June 1993 - Sept.1997 Research Associate, Medical University of South Carolina (MUSC),

Charleston, SC, USA. Oct. 1997 - Assistant Professor, MUSC, Charleston, SC, USA and Adjunct Assistant

Professor, MUSC, Charleston, SC, USA from Feb 2000 on. Dec 1999- Dec 2003 Senior Lecturer (full-time), University of Melbourne, Australia. September 2002-2013 Visiting Professor Endocrinology Section, Oklahoma University Health

Sciences Center, OK, USA. Jan 2004-2012 Associate Professor, University of Melbourne, Australia Jan 2013 - Professor and Chair of Diabetes and Vascular Medicine, University of

Sydney, NHMRC Clinical Trials Centre, Camperdown, NSW, Australia Jan 2013 - Honorary appointment Associate Professor University of Melbourne, Dept.

of Medicine, St. Vincent’s. Oct 2013- Professor and Chair of Diabetes and Vascular Medicine, Queens

University, Belfast (20% FTE). HONORS: 1983 Royal Flying Doctor Service Scholarship 1990 Sandoz Medal for Medical Research 1996 Featured researcher in Diabetes Forecast Article (December) 1997 Invited participant (of 40 worldwide) EASD / JDFI Diabetic Retinopathy Workshop.

Oxford, England. 1998 Invited attendee (of 25 worldwide) EASD Scientist Training Course. Seattle, USA. 1998 Prize winner Novo Nordisk International Diabetes Website Competition 2003 Kelly West Lecturer Oklahoma Health Sciences Center, OKC, OK, USA 2003 Featured researcher Diabetes Conquest – Cover story 2003 / 2004 AZTECC cardiovascular clinicians training program (of 20 worldwide) Amsterdam /

London / New York 2004-2012 Australian Diabetes Society Council – elected

Alicia Jenkins 8

2005 American Diabetes Association (ADA) Harold Rifkin award to Insulin For Life for international service to diabetes.

2005 Australian Museum Eureka Award for medical research (an adult human artery

angiogenesis model) that reduces use of animals in medical research (featured in national news, radio and television)

2004 John Lacey Smith Award for Best Presentation at the Annual Microvascular Society

Conference. 2005 University of Melbourne Knowledge Transfer Project Award: A telemedicine Diabetes

Tip of the Day Project MEMBERSHIP OF PROFESSIONAL/SCIENTIFIC SOCIETIES: Diabetes related Juvenile Diabetes Research Foundation International, Juvenile Diabetes Foundation Australia Clinical Research Network American Diabetes Association, European Association for the Study of Diabetes, Australian Diabetes Society, Board Member and Medical Advisor Insulin For Life Australia and Global (a charitable organization that provides diabetes supplies to developing nations or after disasters; www.insulinforlife.org). Founder and manager of Insulin For Life USA (OKC) and Board Member IFL USA (Florida) Vascular Disease related Australian Atherosclerosis Society Hypertension Foundation International Society Resistance Arterioles National Lipid Association (USA) European Society for Atherosclerosis General Association of Clinical Scientists (USA) International Malliard Reaction Society (IMARS) Academic Institution related Collegiate Member, Royal College of Physicians, Edinburgh, Scotland, University of Melbourne Alumni, St. Mary’s College Alumni

Alicia Jenkins 9

REVIEW DUTIES JOURNALS: Diabetes related Diabetes Diabetes Care Diabetic Medicine Diabetologia Diabetes Research and Clinical Practice Journal of Diabetes and its Complications Clinical Endocrinology Metabolism Diabetes, Metabolism, Research and Reviews Vascular Disease related Atherosclerosis Journal of Lipid Research Circulation Journal of Translational Cardiology General medicine related Journal of Clinical Investigation Comparative Biochemistry and Physiology Proceedings of the National Academy of Science (USA) American Journal of Physiology Free Radicals in Biology and Medicine Kidney International Journal of Clinical Science Clin Chem Acta. Clinical Science Obesity Renal medicine related Nephrology Kidney International Nature Reviews Nephrology Clinical Journal American Society of Nephrology CONFERENCE ABSTRACT REVIEW: 1991 European Association for the Study of Diabetes (EASD) Conference, Dublin, Ireland 2002 World Cardiology Conference Sydney, Australia 2003 Australian Atheroslerosis Society / Australian Vascular Biology Conference, Ballarat 2004 International Maillard Conference, Charleston, SC, USA 2006-8 Organizing Committee Western Pacific region IDF conference (2008) 2007 Australian Diabetes Society Poster Prize Judge 2009 Australian Atherosclerosis Society 2009-12 Australian Diabetes Society (ADS) abstracts 2011 ADS poster and junior investigator oral prizes

Alicia Jenkins 10

GRANT REVIEW DUTIES: 1997 Reviewer University Research Council grants. Medical University of South Carolina. 1998-2000 Monthly review of all clinical research grants proposing to use the MUSC General Clinical

Research Center. 1998 NIH Study Section. Diabetes Complications. Washington, DC. August 1998 1999 JDFI Study Section. San Francisco, CA. July 1999. 1999 JDFI Study Section for Program Project Grant. San Francisco, CA. July 1999. 1999 American Diabetes Association / Lions SightFirst Program. Ft. Lauderdale, May 1999. 1999 MUSC Summer Undergraduate Research Program. Charleston, April 1999. 2000-2007 Cardiovascular Lipid Research Program. Parke Davis Pfizer, Australia. 2000-2006 Diabetes Australia Research Trust. 2000-2002 Ophthalmic Research Institute of Australia 2001-2003 Reviewer / National interview panel for Australian National Heart Foundation 2002 National interview panel for Australian National Heart Foundation 2002-2004 Australian National Health and Medical Research Council (NHMRC) 2002 Australian Arthritis Foundation 2002 NIH Study Section (Diabetes) Bethesda, MD, USA. October 2002 2003 Australian NHMRC Review Panel (7B) and general reviewer 2003 Austrian Medical Research Council 2004-2008 National Heart Foundation Australia 2002-2012 Diabetes Australia Research Trust (DART) 2006 Australian NHMRC Review Panel (Liver disease, obesity, GIT, diabetes, nutrition) 2007 Australian NHMRC Review Panel (Liver disease, obesity, GIT, diabetes, nutrition) 2006 Australian Diabetes Society Lilly Diabetes Research Grant Program (Chairperson) 2007 Australian Diabetes Society Lilly Diabetes Research Grant Program (Chairperson) 2007 Hong Kong Medical Trust 2007 Australian Diabetes Society Servier National Action Plan Grants 2008 Chair Australian NHMRC Review Panel (Liver disease, obesity, GIT, diabetes, nutrition) 2009-10 NHMRC Career Development Award Review Panel 2010 Diabetes Australia Research Trust Review Panel (assigning reviewers, result review) 2010 -11 Australian High Blood Pressure Research Foundation Fellowship 2011-12 UK Medical Research Foundation 2012 NHMRC Project Grants 2011-12 University of Melbourne Scholarship Programs 2012 JDRF International 2013 NHMRC Career Development Fellowships 2013 JDRF Australia Clinical Research Network grants (Seed grants and Fellowship) THESIS EXAMINATION 2002 University of Melbourne Honours Theses re Diabetes Complications 2003 University of Melbourne Honours Theses re Diabetes Complications 2004 University of Melbourne Honours Theses re Diabetes Complications 2003 University of Melbourne BMedSci Thesis Examiner re Diabetic Nephropathy 2005 University of NSW Honours Thesis re AGEs and Diabetes Complications 2004 University of Melbourne BMedSci Thesis Examiner re Islet Cell Tissue Engineering 2004 University of Melbourne Honors Thesis re Diabetic Cardiomyopathy 2004 University of Sydney PhD Thesis. AGE modified LDL. 2005 University of Sydney PhD Thesis. Cell Adhesion Molecules in Diabetic Nephropathy 2005 University of Western Australia PhD Thesis. Lipoprotein kinetics

Alicia Jenkins 11

2006 University of Melbourne Honors Thesis re Diabetes Complications and a Novel Drug 2007 University of Melbourne Honors Thesis re Diabetic Cardiomyopathy and ACE system 2008 University of Oslo, Norway PhD thesis re AGEs and diabetic retinopathy (1st opponent) 2009 University of Sydney PhD Thesis. HDL dysfunction 2009 University of Western Australia PhD Thesis. Oxidative Stress 2010 University of Melbourne Masters Telephone Coaching in Diabetes Care 2010 University of Adelaide PhD Thesis. Diabetic Retinopathy and Its Genetics 2011 University of Melbourne Honours Thesis re Liver Disease and Diabetes 2011 University of Melbourne, BMed Sci Thesis re ALT and diabetes 2011 University of Melbourne, BMed Sci Thesis re insulin producing cells in brain 2014 University of Sydney, PhD Efficacy and Cost-effectiveness of weight loss programmes for

overweight and obesity in adults OTHER ASSESSMENTS 2009 IMARS essay competition judge CLINICAL EXAMINER 1992 4th year medical students Trinity College Dublin - final clinical medicine 2003 4th year medical students University of Melbourne, OSKE medicine exam 2004 Final (6th) year medical students University of Melbourne, OSKE medicine exam 2005 5th year medical students University of Melbourne, OSKE medicine exam 2005 Final (6th) year medical students University of Melbourne, OSKE medicine exam 2006 5th year medical students University of Melbourne, OSKE medicine exam 2007 Nurses Board of Australia for Nurse Practitioner Accreditation in Diabetes 2008 4th year medical students University of Melbourne, OSKE medicine exam 2009 4th year medical students University of Melbourne, written medicine exam 2009 Nurses Board of Australia for Nurse Practitioner Accreditation in Diabetes 2010 4th year medical students, University of Melbourne, OSKE exam 2011 4th year medical students, University of Melbourne, OSKE exam 2011 6th year medical students, University of Melbourne, OSKE exam 2012 Semester 8 and 9 medical students, University of Melbourne, OSKE exam 2008-2012 Written questions medical student exams University of Melbourne

COLLABORATIONS National

Royal Prince Alfred Hospital Campus, Sydney Endocrinology Unit, Lipid Clinic

St Vincent’s Melbourne Campus

St. Vincent’s Hospital Melbourne Units Cardiothoracic Unit Cardiology Unit Endocrinology Rheumatology Unit Renal Unit Psychiatry Unit

Alicia Jenkins 12

Department of Medicine, James Best, FRACP, MD, Glenn Ward, FRACP, PhD, David O’Neal, FRACP, MD, Darren Kelly, PhD, Ian Trounce, PhD, Harshal Nandurkar, FRACP, PhD, Petrova Lee FRACP, MD, Andrew Wilson, FRACP, PhD, Bernard O’Brien Institute Greg Dusting, PhD, Anand Hardikar, PhD St. Vincent’s Institute, Bruce Kemp, PhD, Jock Campbell, FRACP, PhD, Tom Kay, FRACP, PhD, Stuart Mannering, PhD, Bala Krishnamurthy, FRACP, PhD University of Melbourne Department of Ophthalmology: Tien Wong, MBBS, FRACO, FRCS, MPH, PhD, C. Alex. Harper, FRACO, FRCS. Jonathan Crowson, FRACO, FRCS, PhD; Ecosse Lameroux, MD Department of Biochemistry / BIO21: Geoff Howlett, PhD Department of Paediatrics Royal Childrens Hospital, Fergus Cameron, FRACP, MD, Michelle O’Connell, FRACP, MRCPI, MD, Mary White, MBBS, MRCPI Department of General Practice Doris Young, MBBS, John Furler MBBS, Irene Blackberry, MBBS Royal Melbourne Hospital. Professor Peter Colman, A/Prof. Danny Liew, FRACP, PhD.

Australia University of Sydney: Anthony Keech, FRACP, PhD and FIELD study investigators, Stephen Twigg, FRACP, PhD, Sue McLennan, PhD, Paul Mitchell, FRACO, PhD, Ian Caterson, FRACP, Anand Hardikar PhD, Sven Bursell PhD., David Sullivan, FRACPath. Children’s Hospital at Westmead (Sydney): Kim Donaghue, FRACP, PhD, Maria Craig, FRACP, PhD Heart Research Institute (Sydney): Phil Barter FRACP, PhD, Kerry Anne Rye FRACP, PhD, Michael Davies PhD, Martin Ng, FRACP, PhD Royal Melbourne Hospital: Peter Colman, FRACP, PhD, Alison Nankervis, FRACP, PhD, Jenny Conn, FRACP Monash Helena Teede, FRACP, PhD, Christine Rodda, FRACP, PhD Western Hospital Shane Hamblin, FRACP Baker IDI: Neale Cohen, FRACP, Merlin Thomas, FRACP, PhD, Alex Brown, MBBS, PhD, FRACP (Alice Springs), Peter Miekle, PhD University of Western Australia: Gerald Watts, FRACP, PhD, Tim Davis, FRACP, PhD, Wendy David PhD, Kevin Croft, PhD, Trevor Mori PhD Melbourne Collaborative Cohort Study (MCCS) related: Dallas English, PhD, Andrew Tonkin, FRACP, PhD, Graham Giles, PhD FAMAS Study and T4DM Study Gary Wittert, FRACP, PhD. University of Adelaide Garvan Institute Kathy Samaras, FRACP, PhD

Alicia Jenkins 13

Deakin University Bodil Rasmussen PhD. Trish Dunning, RN, PhD, Jane Speight, PhD, Christel Hendriex, PhD Adelaide: Prof. Kerin O’Dea PhD; Prof. Gary Wittert, FRACP; Prof. Michael Horowitz

International Major Cohorts

Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications (DCCT / EDIC) Veteran’s Affairs Diabetes Trial (VADT) Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) PROGRESS (completed) Pre-eclampsia in Type 1 diabetes pregnancy (Australia, Norway, USA) REMOVAL Study (Metformin in Type 1 Diabetes) John Petrie, FRCP, MD University of Glasgow

Institutions Medical University of South Carolina: Richard Klein, PhD, Maria Lopes Virella, MD, PhD, Gabe Virella MD, PhD, W. Timothy Garvey, MD, PhD, Daniel Lackland, PhD Oklahoma University Health Sciences Center Timothy J Lyons, MD, FRCP, Jian-Xin Ma, MD, PhD, Sarah Zhang, MD, Ming Zhou, MD, PhD, George Dale, PhD, Chris Aston, PhD, Julie Stoner, PhD University of Missouri Michael Hill, PhD University of Hawaii Sven-Erik Bursell, PhD, Jo Humphries, MD Oslo University Kristian Hannsen, MD, PhD Inserm Paris, France John Chapman, FRCP, PhD University of Otago Greg Seymour, DDS (Dental Faculty Dean), Mary Cullinan, DDS GRANT FUNDING: EXTRA-MURAL GRANT FUNDING AS PRINCIPAL OR CHIEF INVESTIGATOR: Current: 2014-2018 NHMRC Project Grant FAME-1 EYE . Fenofibrate and the Microvascular Complications of Type 1 Diabetes. CIA. CIB K Donaghue, CIC D O’Neal CID J Best $2,754,608

Alicia Jenkins 14

2014-2015 NHMRC Project Grant. The protective effects of fenofibrate in diabetes-related susceptibility to ischaemia. CIB to CIA Martin Ng. $609,505 2013-2015 NHMRC FIELD LIFE. Epigenetics of Type 2 diabetes complications. CIC to CIA Keech AUS$1.09 million 2011-2015 REMOVAL study: REducing with MetfOrmin Vascular Adverse Lesions in type 1

diabetes. JDRF Grant Number: 17-2011-272 US$3,216,000 Co PI to John Petrie UK. 2011-2015 REMOVAL sub-study: REducing with MetfOrmin Vascular Adverse Lesions in type 1

diabetes. JDRF Australia AUS$335,000 PI 2014-2015 JDRF International. Closed Loop Insulin Pumps in the Home. CIC to CIA D O’Neal. US$900,000 2012-2014 Fred Hollows Foundation. TEAMSNET Telemedicine for Diabetes Eye Care. CIB to CIA Sven Bursell AUS$3 million 2011-2014 NHMRC Partnership Grant Telemedicine for Diabetes and Cardiovascular Disease Care. CIB to CIA Sven Bursell AUS$1.8 million 2010-2012 NHMRC Unlocking the genetics of diabetes complications (FIELD Study) CIB to CIA A Keech AUS$2.4 million 2012-2014 NHMRC Testosterone for the Prevention of Type 2 Diabetes. T4DM CI to CIA G Wittert AUS $4.2 million. 2012 Rebecca Cooper Equipment Grant Retinal Camera $22,000 2012 St Vincents REF: Insulin levels in Type 1 diabetes patients $15,000 2010-2012 Investigator Initiated Industry (Sanofi Aventis and Medtronic) Funded Study re General Practice based Insulin Commencement in Type 2 diabetes with Continuous Glucose Monitoring Support. 16 Melbourne based centres. Co-I with David O'Neal AUS$480,000 2010-2012 Novo Nordisk Diabetes Tip of the Day telehealth project. AUS$7000 2011-12 ADS Servier National Action Plan. A Diabetes Tip Website AUS$20,000 2011-13 Telematics Trust. A Diabetes Tips Website AUS$30,000 Past: 1989-1990 MSD Fellowship in Lipid Metabolism. AUS $30,000 / year 1993 S.W. Shields RACP Fellowship. LDL oxidizibility in diabetes. AUS $3000 1993 Australian National Heart Foundation Travel Scholarship

Alicia Jenkins 15

1995-1997 ADA - Lions SightFirst Diabetic Retinopathy Research Program Training Grant. Modified lipoproteins in the pathogenesis of diabetic retinopathy, and the effects of Vitamin E supplementation. US$80,000.

1995-1997 Juvenile Diabetes Foundation International Research Grant.

Modified lipoproteins in the pathogenesis of diabetic nephropathy, and the effects of Vitamin E supplementation. US$100,000.

1998 ADA-Lions SightFirst Research Program. Molecular mechanisms of diabetic retinopathy. Equipment Grant. $15,000.

1997-1999 ADA-Lions SightFirst Research Program. Glycoxidation, lipoproteins and diabetic retinopathy (Training Grant). $ 80,000. 1997-1999 Juvenile Diabetes Foundation International (Research Award) Glycoxidation, lipoproteins and diabetic angiopathy. $200,000 1999-2000 Diabetes Research and Wellness, Diabetic Vascular Disease. $120,000 1999-2000 American Diabetes Association Research Award Lipoprotein subclasses in the DCCT /

EDIC cohort. $100,000. 2000-2003 American Diabetes Association Research Award: NMR Lipoprotein subclasses in the

DCCT/EDIC cohort. $300,000. 1999 Parke-Davis / Pfizer CVL research grant AUS$50,000 1999 RACP High Blood Pressure Fellowship. Lp(a) and LDL and atherosclerosis.

AUS$60,000 2000-2001 National Heart Foundation Clinical Research Fellowship AUS$69,000 2001 Eli Lilly Diabetes Research Program AUS$20,000 2001 Novo Nordisk Diabetes Research Program AUS$9,700 2000-2002 Juvenile Diabetes Foundation International (Research Award) Glycoxidation, lipoproteins

and diabetic angiopathy. US$255,525 2002 Travel Grant to attend American Heart Association Meeting AUS$1800. 2002 Arthritis Foundation of Australia. Wyeth Grant in Aid. Novel Risk Factors for and the

Detection of Heart Disease in Rheumatoid Arthritis. AUS$10,000. 2002 Rebecca Cooper Foundation Equipment Grant - Glutathionyl Hb. AUS$16,000

2003 Rebecca Cooper Foundation Equipment Grant. Models of vascular damage in diabetes. Coulter Counter AUS$16,000

Alicia Jenkins 16

2003 Collier Charitable Foundation Equipment Grant. Models of diabetic retinopathy. AUS$10,000

2003 Novo Nordisk Regional Diabetes Support Scheme. Diabetes Website. AUS$3,000 2003 Novo Nordisk Regional Diabetes Support Scheme. Diabetes, inflammation and oxidation

as risk factors for cardiovascular disease in Indigenous Australian communities. Co-PI K Rowley. AUS$7,000

2003 Eli Lilly Diabetes Research Program HDL Function in Diabetes AUS$15,000 2003 Ophthalmic Research Institute of Australia. Novel vascular disease risk factors in diabetic

retinopathy. AUS$30,000 2004 Novo Nordisk Diabetes Research Award. Microvascular dysfunction in Diabetes.

AUS$4,900. Co-PI MJ Hill. 2000-2004 National Heart Foundation Clinical Research Fellowship Novel vascular disease risk

factors AUS$40,000p.a. 2002-2004 Diabetes Australia Research Trust Millenium Grant. Paraoxonase and AGEs in the

microvascular complications of Type 1 diabetes. AUS$150,000. 2003-2005 American Diabetes Association Lions SightFirst. Markers of Diabetic Retinopathy.

US$160,000 2005 Ophthalmic Research Institute of Australia. LMW-AGEs, Fatty Acid Oxidation Products

and Diabetic Retinopathy. AUS$22,000 2005 Novo Nordisk DAWN Award Insulin For Life AUS$4000 2004 Ophthalmic Research Institute of Australia. PEDF in Diabetic Retinopathy. AUS$14,100

2005-2006 NHF Fellowship Novel CAD risk factors, HDL function and models of angiogenesis AUS$60,000pa

2005-2006 NHF Grant LDL and HDL effects on microvascular function. AUS$60,000 Co-PI Mike Hill 2006 Harvard Australia Foundation Fellowship for visit by A/Prof Bursell AUS$35,000 2006 Novo Nordisk DAWN award Oral history Type 1 diabetes $5000 2006 Novo Nordisk Diabetic Artery Explant model $5000 2006-2007 RACP Krongold-Heath Fellowship $25,000 Tissue AGEs in Type 2 diabetes 2006 Vascular Tissue Repository St. Vincent’s Research Foundation AUS$30,000 2007 -08 Eli Lilly Diabetes Grant ADMA in Type 1 diabetes AUS$5000

Alicia Jenkins 17

2007 -08 Servier ADS Diabetes National Action Plan. Vascular tissue in diabetes AUS$20,000 2008 RACP Vincent Fairfax Fellowship. Vascular Disease in Diabetes AUS$60,000 2007-2009 NHMRC HDL dysfunction in Type 2 diabetes and coronary artery disease. AUS$322,000

(CIA) 2007-2009 NHMRC . Biomarkers and genetic determinants of cardiovascular risk in diabetes: the FIELD

study. AUS$1,894,800 (CI-B) 2009 Novo Nordisk An ultraportable low cost retinal camera for assessment of diabetic retinopathy. AUS$8000 2008-09 Servier ADS Diabetes National Action Plan. 1,5 Anhdroglucitol in diabetes AUS$22,000 2007-2010 Medtronic. Investigator Initiated ALGOS Study re sensor augmented insulin pumps and a

patient decision support algorithm. (Co-PI D O’Neal and JD Best) 2009-2010 RACP CPD related to Insulin Pumps and Continuous Glucose Monitoring. 1 day seminar:

Insulin pumps and glucose sensors. What the non-endocrinologist should know. Completed March 2010.

2006-2011 Project leader on Program Grant (JDRF and NHMRC) AUS$100,000 pa. Insulin resistance, inflammation and oxidative stress in islet transplant recipients. Overall PI Tom Kay AUS$2million p.a.

2007-2011 NHMRC. Clinical Centre for Research Excellence in Diabetes. AUS$2,000,000 (CI to PI J

Best) 2008-2011 NHMRC. Retinal grading and complications in Type 1 diabetes. AUS (CI to CIA Tien

Wong) 2010-2012 NHMRC FAMAS study. CIE to CIA G Wittert AUS$1.7 million EXTRA MURAL GRANT FUNDING AS CO-INVESTIGATOR: Current: 2012-2015 American Diabetes Association. PEDF and NMR determined lipoproteins in Type 1 and Type 2 diabetes. With PI TJ Lyons US$600,000 2013 Australian Diabetes Society. Diabetic Retinopathy Assessment – Low cost cameras with L

Brazionis. AUS$50,000 2013. Australian Diabetes Society. Insulin pumps and basal rate change pharmacokinetics. With Dr S

McAuley. AUS$50,000 2013 Diabetes Australia Research Trust: Glycaemia in ICU patients. With Adam Deane

AUS$60,000

Alicia Jenkins 18

2013 NHMRC Predicting response to fenofibrate (using NMR lipidomics) in the FIELD study. AI

to CIA Peter Miekle. AUS$692,000 2012-2014 JDRF Australia Clinical Research Network Trainee. Supervisor of Dr Andrzej Januszewski $60,000 2009-2011 NIH (USA) Lipoproteins and PEDF in the Vascular Complications of Diabetes with TJ Lyons and the DCCT / EDIC and VADT. US$1,200,000 Past: 1994-1996 American Diabetes Association, Lions Clubs Affiliates Research Award. "The

glycoxidation hypothesis and the pathogenesis of diabetic retinopathy". US$80,000. 1996 American Diabetes Association, Lions Clubs Affiliates equipment grant. Modified

lipoproteins and apoptosis in diabetic retinopathy, and the effects of vitamin E supplementation. US$17,155. PI: TJ Lyons, MD.

1996-1998 American Diabetes Association, Lions Clubs Affiliates Research Award. Mechanisms of

retinal capillary injury by modified LDL. US$80,000. PI: TJ Lyons, MD. 1994-2000 National Institutes of Health, R29. "Glycoxidation and diabetic retinopathy". US$348,373.

PI: TJ Lyons, MD. 1996-1999 NIH Program Project Grant: Markers and mechanisms of macrovascular disease in IDDM.

Co-investigator Project 1 (of 5), Project Leader, TJ Lyons, MD: Glycation, oxidation and glycoxidation in the pathogenesis of accelerated macrovascular disease in diabetes. Total budget: US$3,250,000. PI: W.T. Garvey, MD.

1998-2001 Juvenile Diabetes Foundation International, Program Project Grant Supplement: Markers

and Mechanisms of Macrovascular Disease in Insulin Dependent Diabetes Mellitus. Project Leader of Project 1 (of five component projects, three core facilities) TJ Lyons, MD: "Glycation, Oxidation and Glycoxidation in the Pathogenesis of Accelerated Macrovascular Disease in Diabetes". Project 1: $109,000; Program Project: $728,000

1999 NIH KO3 award. SERMs in a micro-pig model of atherosclerosis. $75,000. PI JA

Goodrich. 1997-2001 Merit Review Grant: In vivo glycated LDL and atherosclerosis. US$400,000. PI: R.L.

Klein, PhD 2001 CVL Parke Davis Pfizer Award. PI C Nelson. AUS$55,000. 2002 CVL Parke Davis Pfizer Award. PI A Wilson. AUS$55,000. 2002 CVL Parke Davis Pfizer Award. PI K McLaughlin. AUS$50,000. 2001-2003 National Heart Foundation. Cardiovascular disease risk factors in the Indigenous

community. PI K Rowley. AUS$240,000

Alicia Jenkins 19

2002 SLE Foundation. Vascular health and risk factors in SLE. PI T Godfrey AUS$30,000 2002 Novo Nordisk Award: HDL size in diabetes. PI D O’Neal AUS$7,000 2002 Novo Nordisk Award: RAGE polymorphisms in diabetes. PI E Glare AUS$7,000 2001-2002 NHF #R00M 0007: Effectiveness of community interventions to improve vascular

compliance and oxidative stress in Aboriginal people”, PI: KG Rowley. $80,000 2002 Collier Charitable Foundation Equipment Grant. Cell culture models of vascular damage.

AUS$10,000 PI James Best 2003 Collier Charitable Foundation Equipment Grant. Oxidative stress measures in diabetes and

vascular disease. AUS$10,000 PI K Rowley. 2004-2003 NHMRC grant. The ApoE Interactome. PI: Matt Periguini 2004 Novo Nordisk Diabetes Research Award. Mechanisms of Diabetic Retinopathy.

AUS$4,900. PI J Best. 2002-2004 Juvenile Diabetes Research Foundation Research Grant: Markers and Mechanisms for Pre-

Eclampsia in Women with Type 1 Diabetes. US$750,000. 2003-2005 NIH: Novel vascular disease risk factors in the PROGRESS Study. US$200,000 PI Jock

Campbell. 2005 Periodontal disease and cardiovascular disease in diabetes. National Diabetes Action Plan

AUS$20,000 PI H Schlen 2002-2006 Compositional changes in LDL in diabetes and effects on endothelial function. VA Merit

Award PI R Klein. US$500,000 2004-2006 Lipoprotein Subclasses in Diabetic Nephropathy. Presbyterian Health Foundation.

US$79,000 PI TJ Lyons. 2001-08 NIH Program Project Grant: Markers and Mechanisms of Vascular Disease in Diabetes.

Co-Project Leader Project 1 (of 4) with TJ Lyons: Lipoproteins and Oxidative Stress. Project 1 budget: US$2,500,000. Total budget: US$9,510,942. PI: W.T. Garvey, MD.

2005-2008 Lipoprotein subclasses and vascular complications in the DCCT/EDIC and VADT. NIH.

US$250,000 CoPI of Project 1 with TJ Lyons 2007-08 ADS Diabetes National Action Plan Grant. Periodontal tissue in diabetes PI H Schlen

AUS$20,000 2007-08 ADS Diabetes National Action Plan Grant. Transition in Type 1 diabetes PI B Rasmussen

AUS$20,000

Alicia Jenkins 20

2005-2009 National Health and Medical Research Council of Australia, Project Grant # 299852 PI K Rowley and K O’Dea. Predictive models and interventions for coronary heart disease in Aboriginal and Torres Strait Islander people AUS$3,500,000

2008 JDRF (International) Innovative Grant Mitochondrial mutant mouse as a model of diabetes complications. PI Ian Trounce. US$110,000

2009 Ramaciotti Grant. Oxidative Stress and Diabetic Vascular Disease PI S deDios. $30,000 2008-2010 JDRF (International) Retinal vessel grading to predict Type 1 diabetes Complications. PI

T Wong. 2008-2010 NHMRC Retinal vessel grading to predict Type 1 diabetes Complications. PI T Wong. 2010-11. Deakin University. Transition to Motherhood for Women with Type 1 diabetes. PI B

Rasmussen. AUS$25,000 2010-2011 Deakin University: Psychosocial aspects of Type 1 diabetes care and motherhood. PI

Bodil Rasmussen $25000 2011 2010-2011 Novo. Psychosocial aspects of Type 1 diabetes care and motherhood. PI

Bodil Rasmussen $7000 2009-2011 National Heart Foundation. Retinal Vascular Health and Diabetes Complications. PI A

Keech. $120,000 INTRAMURAL GRANT FUNDING AS PRINCIPAL INVESTIGATOR: Current 2014 Uni. Of Sydney NHMRC Equipment Grant application. Corneal Confocal Microscopy.

$40,000 2012-2013 St Vincent’s Research Foundation. Vascular Risk Factors in CSII vs. MDI treated Type 1

diabetic patients $15,000 2012-2013 St Vincent’s Research Foundation. C-Peptide levels in Type 1 diabetes patients. $15,000 2013 University of Sydney Summer Student Program. Metformin in Type 1 diabetes New New

Tun $2400

Past 1990 St. Vincent's Hospital Research Grant. Lp(a) in Diabetes. AUS$2,500 1993 MUSC Post-doctoral Fellowship. Lipoprotein oxidizibility in diabetes. US$20,000 1996 MUSC/University of South Carolina. Plasma Advanced Glycation End-Products (AGEs) in renal failure and diabetes. Co-PI: Deanna Cheek, MD. US$20,000 1996 Mentor to Cliff Perez: MUSC Summer Undergraduate Research Program. US$2,800

Alicia Jenkins 21

1997 Lipoprotein toxicity to microvascular cells. MUSC Equipment grant US$15,000 1998 Mentor to Arthur Baker: MUSC Summer Undergraduate Research Program. US$2,900 1997 Mentor to Lacy Pounder: MUSC Summer Undergraduate Research Program. US$2,900 1999 Mentor to Ebony Fulcher: MUSC Summer Undergraduate Research Program US$2,900 2003 University of Melbourne Visiting Scholar Award for Dr Alan Stitt. AUS$6,000 2004 University of Melbourne RAGS Scheme Equipment Grant Ocular Fluorimeter

AUS$56,000 2005 University of Melbourne RAGS Scheme. Ocular Fluorimetry as a measure of tissue AGE

content and predictor of vascular disease risk. AUS$45,000 2007 University of Melbourne. Ultracentrifuge, rotors and accessories. AUS$75,000 2008 University of Melbourne. GC/MS and HPLC analytical package AUS$50,000 2008 University of Melbourne Visiting Scholar Scheme. Prof. Sven-Erik Bursell. University of

Hawaii at Manoa. $4000 towards 2 month visit. 2009 Uni. of Melbourne Equipment Grant. Biochemical Autoanalyzer AUS$75000 2009-10 Uni. of Melbourne / Uni. of Hawaii Telemedicine AUS$19,000 2010 St Vincent’s Research Foundation. Vascular Risk Factors in CSII vs. MDI treated Type 1

diabetic patients 2009-12 Uni. of Melbourne Knowledge Transfer Project Grant Telemedicine AUS$10,000 2011 University of Sydney Equipment Grant (with AC Keech) for Autoanalyzer $50,000 INTRAMURAL GRANT FUNDING AS CO-INVESTIGATOR: Past 1998 Vascular Disease Risk Factors in Australian Aborigines. St Vincent’s Hospital Award. PI. K

Rowley. AUS$5,000 1999 Non-invasive assessment of cardiovascular risk in Aboriginal people, AUS$4,000 St

Vincent’s Hospital Research Foundation 2000 Markers of atherosclerosis - Equipment grant. $15,000. PI: J Goodrich, DVM. 2001 Effects of Leveormeloxifene on Atherosclerosis in the Yucatan Micropig $25,000. PI: J

Goodrich, DVM.

Alicia Jenkins 22

2002 Oxidative Stress and HDL function in ESRD. St Vincent’s Hospital Research Foundation

Award. PI. P Lee. AUS$4,000 2003 Vascular Disease in Rheumatoid Arthritis. St Vincent’s Hospital Award. PI. M Wong.

AUS$3,000 2001 Novel Vascular Risk Factors in Renal Diseases. St Vincent’s Hospital Research Foundation

Award. PI. P Lee. AUS$5,000 2002 Non-invasive measures of vascular health in Type 2 diabetes. St Vincent’s Hospital Award. PI.

D O’Neal. AUS$5,000 2002 Kringle 5 and angiogenesis AUS$6,000 PI A Dudley St Vincent’s Hospital Research

Foundation 2004 Measures of oxidative stress in diabetes complications. PI Andrzej Januszewski, AUS$3000

St Vincent’s Hospital Research Foundation 2004 JAK/STAT pathway in vascular endothelial cells PI A Dudley AUS$5000 St Vincent’s

Hospital Research Foundation 2005 SSAO activity in diabetes and vascular disease PI A Januszewski AUS$5000 St Vincent’s

Hospital Research Foundation 2005 Continuous glucose monitoring in gestational diabetes PI D O’Neal AUS$5000 St Vincent’s

Hospital Research Foundation 2005 Dental health and vascular disease. PI H Schlen. AUS$5000 St Vincent’s Hospital Research

Foundation 2006 Insulin Resistance in Type 1 diabetes. PI N Sachithandan AUS$8000 St Vincent’s Hospital

Research Foundation 2006 Diabetic Artery Explant Model PI A Januszewski AUS$8000 St Vincent’s Hospital Research

Foundation 2006 COAT Platelets in ESRD PI P Lee AUS$5000 St Vincent’s Hospital Research Foundation 2006 Continuous Subcutaneous Glucose monitoring PI D O’Neal AUS$3000 St Vincent’s Hospital

Research Foundation 2006 CG/MS and HPLC for oxidative stress measures. University of Melbourne RAGS scheme. PI

Dr Kerin O’Dea $60,000 2007-08 University of Melbourne RAGS Scheme. Blood pressure monitoring in renal disease. PI

Allison Williams. AUS$14,800

Alicia Jenkins 23

2008 St Vincent’s Foundation. Glycaemic variability in diabetes and perioperative management. PI D O’Neal AUS $8000

2009 Oxidative stress and inflammation relationships with glycaemic variability in Type 1 diabetes.

PI Andrzej Januszewski MENTOR TO STUDENTS and POST-DOCTORAL FELLOWS: includes scholarships and awards

Undergraduate Short Term Students Research

1996-� Karina Timmins. Monash University, Australia. PhD Student. LDL oxidizibility.

1996-� Ming Lo. Monash University, Australia. PhD Student. LDL oxidizibility and LDL size in diabetes and renal failure.

1996-� Karina Moller. BA. Prevent Blindness America, Fight for Sight Research Division Student

Fellowship. Co-Mentor (with TJ Lyons). Retinal capillary cell injury by LDL. US$1,500.

1996-� Cliff Perez. Senior Medical Student. NIH funded MUSC Medical Student Research Program. Glycoxidation Products in Red Blood Cell Membranes – effects of glycemic control.

1996-� Brendan Smyth. Senior Medical Student Research Rotation. Glycoxidation products

and their relationship to diabetic microvascular complications. First prize winner at regional American College of Physicians meeting.

1996-� Elizabeth Beck. MUSC Summer Undergraduate Research Program. Calpain and

apoptosis in diabetic microangiopathy.

1996-� Arthur Baker MUSC Summer Undergraduate Research Program. Macrovascular Disease Risk Factors in Diabetic Microvascular Disease.

1996-� Keith Manning Summer Undergraduate Research Student. AGEs and CML in human

serum fractions. 1998 Lacy Pounder. MUSC Summer Undergraduate Research Program. Modified

lipoproteins, Clotting, and Vascular Tone in Diabetic Vascular Disease. First prize winner 1998 MUSC Student Research Day.

1997-1998 Michele Hoggatt. Junior Medical Student. Novel Macrovascular Disease Risk Factors

and Glycoxidation Products in IDDM. 1996-1998 Arthur Baker MUSC Summer Undergraduate Research Program. Macrovascular

Disease Risk Factors in Diabetic Microvascular Disease. 1999/2000 Fulbright Scholar (to spend one year on collaborative research in Australia). Presentation at “Undergraduate Research on Capitol Hill” (Eighty students were chosen from across USA).

Alicia Jenkins 24

1996-� Arthur Baker, BA. Prevent Blindness America, Fight for Sight Research Division Student

Fellowship. Markers of Diabetic Retinopathy US$1,500. 1997-1998 Physician Assistant Students x 2: Elizabeth Nerbun and Angela Estes. Diabetes and its

complications. 1998-1999 Simone Chinnis. High School Senior. Foot Care in Diabetes. First Class Honors for

thesis. Publication 1998-1999 Leslie Potter. College of Charleston Senior. AGEs in serum subfractions. 1996-� Ebony Fulcher. College Senior. MUSC Summer Undergraduate Research Program.

Lipoprotein binding to matrix.

1996-� Ann Rochini. College Senior. MUSC Summer Undergraduate Research Program. Paraoxonase in Type I diabetes.

2001-02 Summer student research: Nasseem Mirbigani, Chee Lee, James Huang, Harry Wong All

were recipients of Australian National Heart Foundation Summer Student Awards. 2001-02 Summer student research: Melisa Valquez. Recipient of Australian Juvenile Diabetes

Research Foundation Summer Student Awards. sVCAM and HDL in Type 1 diabetes. 1996-� Jacob Cohen, BA. University of North Carolina first year medical student. NIH

Student Research Award and Overseas Research Experience Award. 2000-01 Mark Walter, BSc student. JDFA Summer Student Awardee. PON / HDL function in

Type 1 diabetes. 2000-01 Carol Lee. 4th year medical student. Australian Kidney Foundation Summer Student

Scholarship. Novel vascular disease risk factors in renal disease. 2002-03 Chee Lee. Fifth year medical student. HDL in renal disease. Australian

KidneyFoundation Summer Student Scholarship. 2003-04 Naseem Mirbaghni. CRP and LDL size in relationship to nuclear medicine stress testing.

NHF Summer Student Research Scholarship 2003. 2003-04 Allan Lee 4th year medical student. Novel vascular disease risk factors in SLE. NHF

Summer Student Research Scholarship. St Vincent’s Hospital Young Investigator Award 2004.

2005-06 Zina Valaydon Australian Kidney Foundation Summer Student Scholarship COAT

platelets in ESRD 2006-08 Linda Clapperton, Undergraduate Science Student re diabetes pump clinic database 2010-2012 Daniel Seller. Physiotherapist. Exercise in Type 1 diabetes – preparing for PhD studies

Alicia Jenkins 25

2011-2012 Daniel Calandro Undergraduate Science Student re Type 1 diabetes care, IBM Global

Challenge re non-communicable diseases. Preparing for BSc Honors or Masters studies 2011-2013 Karin Schwartz, medical student. Summer Research Project. QT interval in children with

Type 1 diabetes. (In collaboration Profs. Kim Donaghue, Anthony Keech, Steve Twigg and Nurse Practitioner Marg McGill). University of Sydney Medical Student Summer Research Scholarship and Medical Student Honours Program.

2012-2014 Caroline Traill. Attitudes to Physican Research. University of Sydney Medical Student

Honours Program. 2012-2013 Jailing Chin. Secondary Prevention of Cardiac Disease University of Sydney Medical

Student Summer Research Scholarship. 2012-2013 Jessica Cremore. Statin intolerance and novel treatments. University of Sydney Medical

Student Summer Research Scholarship.

2012-2014 Boris Waldman. HDL and insulin resistance in Type 2 diabetes University of Sydney Medical Student Honours Program.

2013 Kaya Cuper. BSc USA Semester Abroad Uni. Of Sydney Student. Lab Assays and Audits. 2013 Ghada Khamil. BPharm (Egypt). Clinical Researcher Publications. University of Sydney.

Volunteer. 2013-14 Nwe New Tun University of Sydney Summer Student Program. $2400 Metformin use in

adults with Type 1 diabetes 2013-14 Anosh Shiva. University of Sydney Summer Student Program. Statin intolerance. $2400

Co-Supervised with Prof. Keech 2013-14 Joanna Lee. University of Sydney Summer Student Program. $2400 Time to Research the

Medical Researcher. Co-Supervised with Prof. Keech 2013-14 Jack Kirby. University of Sydney Summer Student Program. $2400 AMPKinase in Type 1

diabetes. Co-Supervised with Dr Andrzej Januszewski

Clinical (General Medicine) 1996-� Yanis Bellil Elective final year medical student from the USA (4 weeks)

1996-� Kevin Dan Joyce Elective final year medical student from the USA (6 weeks)

1996-� Thomas Miller Elective final year medical student from the USA (6 weeks)

2004 Arthur Baker Elective final year medical student from the USA (6 weeks)

2006-8 Nedal Alkatib. Elective medical student from RCSI Dublin, Ireland (8 weeks each year).

Alicia Jenkins 26

Undergraduate Research Students (at least one year full time research)

B Medical Science 2000 George Kalogerakis. Bachelor of Medical Science, 5th year Medical Student, University

of Melbourne. Oxidative stress and HDL in diabetes and renal failure. Recipient of University of Melbourne Faculty of Medicine Scholarship. Prize winner 2000 St Vincent’s Research Day. Two travel awards from JDFA, Travel awards and finalist for Young Investigator Awards at Australian Atherosclerosis Society Meeting, the International Oxidants and Antioxidants conference, and the Australian Diabetes Society Meeting. B.Med.Sci passed with Honors and conferred Dec 2002.

2002-03 Nick Mason. Vascular Health in Diabetes and Point of Care testing of Vascular Disease

Risk Factors. Awarded H1 2002-03 Eve Anwar Retinopathy in Type 1 Diabetes. Awarded H2 2002-03 Allan Lee Vascular Dysfunction and Risk Factors in SLE. Awarded H1. Young

investigator award (1st prize) SVH Research Week 2004. 2002-03 John Swan Vascular Inflammation. Awarded H1. 2003-2004 SQ Chan A Novel Model of Angiogenesis and Effects of Diabetes. Awarded H2 Poster

presentations at ADS, Cardiac Society and American Heart Association. Art competition Prize winner SVH Research week 2004.

2003-04 Jasmine Chung Novel vascular disease risk factors in Type 1 diabetic retinopathy and

HDL dysfunction. Awarded H1 2005-06 Zina Valaydon Coated platelets. Awarded H1

1996-� Karan Sinh AGEs and AMPKinase in vascular disease. Discontinued – student transfer.

B Sc Hons

2002 Jade Woon. BSc. Honors Student. Glutathionyl Hb in Type 1 diabetes. BSc Hons (H2A) awarded 2003. Subsequently completed medical school in Tasmania

Fulbright Scholar

1999 Arthur Baker, BA. HDL antioxidant function in diabetes and ESRD 10 months. Subsequently completed medical school, Obstetrics and Gynaecology Training and a neonatal care fellowship.

Medical Registrar Year Research Projects

1997-99 Steven Zygmont, MD. Endocrine Fellow Research Rotation. Glycoxidation products in

diabetic and non-diabetic renal disease. First prize winner at regional American College of Physicians meeting.

1996-� Maria Szpiech, MD. Endocrine Fellow Research Rotation. Glycoxidation products in

diabetes and its complications.

Alicia Jenkins 27

1996-� Ana Cornea, MD, Endocrine trainee Oklahoma, USA. Effects of glucosamine on insulin

sensitivity and endothelial dysfunction 1996-� Luis Casas, MD, Endocrine trainee Oklahoma, USA. Inflammation and endothelial

dysfunction in cystic fibrosis

1996-� Karen Dwyer. Medical (Renal) Registrar. Advanced Training Project. Oxidative stress and HDL function in renal disease. Prize winner 2nd National Registrar’s Conference. Sydney 2000.

2001-03 Ling Toh MBBS, FRACP and Melinda Wong MBBS: Rheumatology Registrars.

Cardiovascular Disease and its risk factors in Rheumatoid Disease. Recipients of Intramural Research Grant Award, Finalist (MW) Royal Australasian College of Physicians Registrar’s Presentations, Finalist (MW) Australasian Rheumatologist Young Investigator Award 2002, Top 5%ile abstract at International Rheumatology Meeting 2002.

2013 Sylvia Xu MBBS. Metformin in Type 1 diabetes.

Masters

2002-2004 Andrea Semler, BA Adiponectin and diabetes complications. Awarded 2004.

MPhil 2013-2014 Daniel Calandro. BSc. PEDF and Kallistatin in Type 2 diabetes complications

MD

2001-2005 Marno Ryan, MBBS, FRACP, MD. NASH and insulin resistance. Recipient Australian Research Council Award (3 years), Australian Gastroenterology Society Fellowship (2 years). Australian Atherosclerosis Society Young Investigator Award 2003. Stanford Post-Doctoral Fellowship. NHMRC 4 yr fellowship.

PhD Completed

1998-2002 Stefo Christov. BSc(Hons). PhD at University of Melbourne. Recipient of 2 University of Melbourne Student Scholarships, 4 Hospital Research Grants, Invited attendee to the EASD 1999 Scientist’s Training Course, recipient of University of Melbourne PORES scholarship for overseas collaborative research. 2 JDF Australia Travel Grants. Prize winner 2000 St Vincent’s Research Day. PhD awarded 2004.2003-2005 Co-ordinator Dairy Industry Research Projects. Intellectual Property Officer Dairy CRC, then Intellectual Property Officer Baker Institute Melbourne.

2000-2005 Andrew Dudley, MSc, PhD at University of Melbourne. Models of human retinal

angiogenesis and mechanisms of diabetic retinopathy. 2000 Fight for Sight Research Division Student Fellowship US$2,100. 2 X SVH PhD student research scholarships (AUS$20,000), a University of Melbourne Faculty of Medicine (AUS$20,000), and a 3 year University of Melbourne International Student Scholarship (AUS$85,000), Best student poster St Vincent’s Research Week 2002, JDRF Travel Award AUS$2,000.

Alicia Jenkins 28

University of Melbourne Gleghorn Scholarship AUS$17,000, St Vincent’s Hospital Research Award $5,000. Post-doctoral fellowship Harvard, Boston 2005. 2008 Assistant Professor, Harvard, Boston.

1996-8 Andrew Wilson, MBBS, FRACP, PhD candidate at University of Melbourne. Oxidative stress

and endothelial dysfunction in premature atherosclerosis. Australian National Heart Foundation Scholarship (3yrs) (AUS$75,000). Finalist Australian Registrars Research Competition. CVL Research Grant. (AUS$55,000), Prize winner St Vincent’s Research Week 2002, Oral presentation and Young Investigator Poster Finalist American Heart Association 2004, Pfizer Postdoctoral Travelling Fellowship. Accepted for Postdoctoral fellowship 2005, Stanford University, John Cooke. NHMRC Fellowship $330,000. 2008- present: Research Fellow University of Melbourne, Cardiologist St Vincent’s and Mercy; Bickart Fellowship University of Melbourne.

2001-08 Craig Nelson, MBBS, FRACP, PhD Candidate (full then part-time) at University of

Melbourne. Oxidative stress and endothelial dysfunction in renal disease. Two faculty of medicine scholarships. One SVH scholarship. Prize winner St Vincent’s Research Week 2001. 3 year Australian NHMRC Scholarship (AUS$75,000). CVL Research Grant. (AUS$55,000) Excellent poster award International Society of Nephrology (ISN), Austria, July 2002. Travel award (AUS$4,000) to present at ISN, Berlin, Germany, 2003. 2009 Head of Renal Unit Western Hospital, Melbourne.

2005-09 Nirupa Sachithanadan.MBBS, FRACP. PhD Candidate at the University of Melbourne.

Insulin Resistance in the Vascular Complications of Type 1 diabetes and Islet Cell Transplantation. NHMRC Scholarship. EASD Training Course (England), JDRF Australia Travel Award, St Vincent’s Research Grant award. EASD Eli Lilly Junior Scientists Training Course (France), RACP JDFA Scholarship $50,000. Nominated TJ Martin Medal 2010. PhD awarded 2010

2004-09 Nadim Elnaser. BSc(Hons), BPharm, MBA, PhD University of NSW. Vascular reactivity

and effects of AGEs. Co-supervisor Mike Hill, PhD. PhD awarded.

2009-2013 Paul Benitez-A. MD, MPH. Paediatric Endocrinologist Trainee, PhD candidate. Plantar

Fascia Thickness and Diabetes Complications in Children with Type 1 diabetes. Chief Supervisor Prof. Kim Donaghue. APEG Annual Scientific Meeting Junior Investigator Awards 2010 and 2011. Young Investigator Award. Rotary Scholarship for Post-doctoral Fellowship for Closed Loop insulin pumps Cambridge University, England. Endocrinologist Children’s Hospital at Westmead and ongoing clinical diabetes research.

Incomplete

2004-05 Leo Rando. MBBS, FRACP. PhD Candidate at University of Melbourne. Insulin Resistance and Vascular Disease. NHMRC Scholarship. Discontinued early 2005 due to family circumstances.

2010-2011 Sybil McAuley, MBBS, FRACP. DMedSci University of Melbourne. University of

Melbourne John Hayden Scholarship 2010. Transferred to part-time research after maternity leave. RACP Scholarship 2011 for part-time study. RACP JDRF Fellowship 2012 accepted and then changed supervisors to Prof. Richard MacIsaac.

Alicia Jenkins 29

In progress

2005-2012 Harris Schlen, BSc(Hons), MSc, BDSc. (Part-time) PhD Candidate. The link between

periodontal and cardiovascular disease. (Part time due to health issues) Studies completed. Thesis submission in 2013.

2006-2013 Ben Ma, BioMed Sci (Hons) PhD candidate. AGEs, AGE inhibitors and Diabetes

Complications. University of Melbourne International Student Full Fee Remission Scholarship and Stipend (3 years) and St. Vincent’s Health Scholarship (3 years) Studies completed. In dentistry course Uni. Of Melb. Thesis submission in 2013.

2010-2013 Ru-dee Ting, MBBS, FRACP. Cardologist. PhD candidate. Diabetic Nephropathy –

Epidemiology and Mechanisms related to Fenofibrate benefit. With Prof. A Keech. University of Sydney Scholarship; NHMRC Scholarship. Thesis submitted May 2013

2010-2013 Kushwin Rajamani, MBBS, FRACP. Cardiologist. PhD candidate Diabetic PVD –

Epidemilogy and Mechanisms related to Fenofibrate benefit. With Prof. A Keech NHMRC Scholarship.

2011-2014 Carol Silberberg. MD, Psychiatrist. DMedSci Candidate (part-time). Mental Health in

Type 1 Diabetes NHMRC CCRE funding (2012) 2013- Yoon Hi Cho. MBBS, FRACP. Paediatric endocrinologist. PhD Candidate. Vascular

Health and Tissue AGEs in Type 1 diabetes and Cystic Fibrosis related diabetes. With Primary Supervisor Prof. Kim Donaghue .

2013-2015 Erin Bell, BVSci. PhD candidate. Beta cell damage and animal models of Type 1 diabetes.

ARC Scholarship. University of Melbourne Scholarship. With Dr. Caroline Mansfield. 2013-2015 John Vrazas, MBBS, Radiologist. DMedSci candidate. Non-invasive measures of vascular

health. With Co-Supervisor Andrew Wilson. 2012-2015 Jon Noonan, BSc, MEcon, MBBS, PhD candidate. Retinal vascular health in Type 1

diabetes and effects of fenofibrate. NHMRC Scholarship. With Ecosse Lameroux

Post-Graduate Research Fellows

Full-time Post-Doctoral Fellows 2002-2003 Eric Glare, PhD. PON and RAGE in diabetes and Vascular Disease. University Lecturer. 1996-� Aino Soro Parvonen, MD, PhD. Finnish Medical Foundations Euro 120,000 for 3 years.

Accepted invitation to relocate to the Baker Institute after 6 weeks. 2004- present Andrzej Januszewski, MD, PhD. Previous Fulbright Scholar. 2007-2010 Stephanie deDios PhD. JDRFI Post-doctoral Fellowship, Peter Doherty NHMRC

Fellowship (4 years), JDRF Australia, Travel Grant 2008, University of Melbourne Early

Alicia Jenkins 30

Career Development Award 2009 ($26,000), Ramaciotti Grant 2009 ($30,000). Now officer with AQIS.

2012-2013 Mugdha Joglekar. PhD. JDRFI Post-doctoral Fellowship. Beta cell biology – from basic to clinical studies in Type 1 diabetes.

Part-time 2007 Christina Jang, MBBS, FRACP. CCRE Fellow 2 days / week related to ALGOS study. Resigned Dec 2007. 2008-2010 Bala Krishnamurthy, MBBS, Indian Endocrinologist, PhD. CCRE Fellow 2 days / week related to patient decision support algorithm for sensor augmented insulin pumps in Type 1 diabetes (ALGOS study). 2008 CK Yeung, MBBS, MRCP, Hong Kong Endocrinologist. Clinical Research Training in Diabetes (June-Dec 2008) related to circulating and tissue AGEs in Type 2 diabetes and novel vascular risk factors in Type 1 diabetes subjects on vs not on an insulin pump. 2009 Joanne Yau, MBBS, BMedSci. CCRE Fellow 1 day / week related to diabetic retinopathy and diabetes care provision. Masters Degree. Ophthalmology trainee. 2007-2009 Maryam Bassirat, BSc(Hons), PhD. 2 days / week re tissue immunohistochemistry. 2010-2012 Daniel Seller. Physiotherapist. Re Exercise in Type 1 diabetes.

Hosted International Visitors (at least 3 day visits) John Baynes PhD and Susan Thorpe, PhD Department of Chemistry and Biochemistry, University of South Carolina, USA. 1 week in 2002, 3 days 2005, 1 week 2008 Matt Wolf, PhD. Department of Physiology, University of South Carolina, USA 1 week 2002 Alan Stitt, PhD. Queens University, Belfast, Ireland. Retinopathy. 2 months 2003 Funding (AUS$15,000) from UK and University of Melbourne. Sven-Erik Bursell, PhD. Harvard University, Joslin Clinic 1 week 2004 Jian-Xing Ma 3 days 2005 Oklahoma University Health Sciences Center re diabetic retinopathy. Sven-Erik Bursell (3 months funded by AUS$30,000 Harvard Australia Senior Fellowship), Alan Clermont, MSc (2 weeks), Dahlia Bursell, BA (1 week) Harvard University, Joslin Clinic 2006 Sven-Erik Bursell, PhD University of Hawaii (1 week x 4, 2 weeks x 2, 2 months by University of Melbourne Visiting Scholar AUS$4000) 2008-10, 2 weeks 2011. With award of NHMRC Partnership Grant for Telemedicine will spend 4 months p.a. in Australia 2011-2015. Deborah Peters, PhD. University of Hawaii 1 week 2008, 1 week 2009

Alicia Jenkins 31

Joseph Humphrey, MD. University of Hawaii 1 week 2008 Bruce Ishimoto, PhD Stanford University / Ocumetrics. Ocular AGEs 3 days 2009 Mark Atkinson, PhD. University of Florida. 4 days. Dec 2012. UNIVERSITY COMMITTEE / MAJOR CONFERENCE ACTIVITIES.

Ireland 1991 Member : Infection Control Committee. Adelaide Hospital, Dublin, Ireland. 1991 Member : Medical Student Education. Trinity College, Dublin, Ireland. 1992 Member : MRCPI (Boards examination) Organizing Committee, Dublin, Ireland.

USA 1996-8 Mentor Summer Student Research Program 1997-9 Judge: Medical University of South Carolina Student Research Day. 1998-2001 Member. Medical University of South Carolina General Clinical Research Committee. Member. MUSC Carolina Summer Undergraduate Review Committee. 2012 Moderated Poster Session Chair. American Diabetes Association Meeting.

Australia 2001-2002 Judge St Vincent's Hospital Research Week. 2002-2003 Organizing committee Australian Atherosclerosis / Australian Vascular Biology

Conference Melbourne 2003 2003-2009 DOM Website Committee, Directions in Research Committee, IT committee 2004-2009 DOM Executive Committee 2005 Judge St. Vincent’s Research Week 2006 Organizer and Chair of University of Melbourne Vision Day – a day of lectures and reearch

presentations related to eye disease. 2005-08 Organizing committee WPIDF Conference Wellington NZ 2008 2007-08 Organizing committee International Resistance Arteries Society Conference, Hamilton

Island, QLD, Australia, Feb 2008 2008 Organizing committee ADS NADC Best Practice in Diabetes Centres. Sydney July 2008.

Organizer and chair of insulin pumps, patients and politics session. 2009 Organizing committee / Chair Hypertension Meeting. Melbourne 2009 2008-10 SVH Research Foundation Committee 2010 Organizer and Chair ADS Symposium re Modern Diabetes Challenges at World Congress

of Internal Medicine, Melbourne. 2010 Australian Diabetes Society Meeting. Sydney. Organizer and Lecturer insulin pumps and

glucose sensors to John Turtle Training Course to 40 Endocrine Trainees from across Australia and Moderated Poster Session Leader.

2013 Australian Diabetes Society Meeting. Sydney. Organizer and Lecturer re continuous glucose sensors to John Turtle Training Course to 35 Endocrine Trainees from across Australia and Moderated Poster Session Leader.

2011-12 Team Captain IBM Global Health Challenge (University of Melbourne was the only Australian University invited to participate) Finalist.

2010-2012 University of Melbourne, Academic Research Affairs

Alicia Jenkins 32

University of Melbourne Related Clinical Teaching 2000-present University of Melbourne, 4th year medical student general medicine clinical case

presentations. Co-ordinator of series in 2000, 2001, 2003, 2004, 2007. 2000-present University of Melbourne, 6th year medical student general medicine clinical case

presentations. Co-ordinator of series for 6th year students 2003 and 2004. 2000-2007 University of Melbourne, 1st year medical student diabetes discussion panel. Four people

living with Type 1 diabetes, a diabetes nurse educator and endocrinologist spend 2 hours discussing diabetes. Subjects are recruited, briefed, notes and handouts provided and the session chaired. Run twice per year.

2000-2007 Lectures (average 4 per year) re diabetes and CVD risk factor management and / or diabetes complications. 2000-present Participation in trial long and short case general medical examinations for St. Vincent’s Medical Students 2000-present Setting of written examination questions for University of Melbourne medical student exams. 2010-present University of Melbourne Research Training Committee (also awards scholarships) 2012 MD (new post-graduate medicine) teaching. Complications of Diabetes ( 3 x year) Overseas medical student elective students for 4-8 weeks. See student mentoring. INVITED LECTURES:

National 1. LDL oxidizibility in diabetes and in renal failure. Grand rounds. Department of Medicine, Monash

University, Melbourne, June 1993. 2. Glycation, Oxidation and the Complications of Diabetes Mellitus. Department of Medicine.

University of Sydney, Australia. July 1995. 3. Vitamin E and Lipoproteins: Potential Role in the Amelioration of Diabetic Retinopathy and

Nephropathy. Department of Medicine. University of Sydney, Australia. July 1995. 4. Lipoproteins in diabetes mellitus. Australian Atherosclerosis Conference. Melbourne, Dec 1999. 5. Lipoproteins and their modifications in diabetes. Heart Research Institute. Sydney, March 2000. 6. Chronic complications of diabetes. La Trobe Uni. Medical Science Students. Melbourne, April

2000. 7. Lipoproteins oxidative stress, and the chronic complications of diabetes. University of Melbourne,

Department of Biochemistry, May 2000.

Alicia Jenkins 33

8. Diabetic retinopathy. College of Optometry. University of Melbourne. August 2000 9. Vascular Complications of Diabetes. St Vincent’s Institute of Medical Research. August 2000

10. Complications of Diabetes: PON and RAGE. National Mutation Research Center, Melbourne.

November 2000. 11. Lipoproteins and diabetic retinopathy. Australian Ophthalmology and Vision Sciences meeting.

December 2000 12. Heart disease and how to prevent it. Rotary Club North Balwyn, Melbourne. January 2001. 13. Cardiovascular Disease Prevention – the GP’s role. Ongoing Education Program for GPs.

a) St Vincent’s Hospital, Fitzroy, Melbourne. April 2001, b) Parkville, Melbourne, September 2001, c) Brunswick, Melbourne, November 2001.

14. Modified Lipoproteins and Cellular Responses Relevant to the Vascular Complications of

Diabetes. Satellite to International Physiology Society Annual Scientific Meeting. RMIT, Melbourne, Australia. September 2001.

15. Vascular Disease Risk Factors and the Complications of Diabetes. Endocrine Meeting, Royal

Melbourne Hospital, Melbourne, Australia. September 2001. 16. Vascular Disease Assessment and Novel Risk Factors – Relevance to Connective Tissue

Diseases. Royal Melbourne Hospital, Melbourne, Australia. October 2001. 17. NMR dysliproteinaemia in the FIELD Study. FIELD Investigators Meeting, Melbourne,

Australia, April 2002 18. Complications of Diabetes. Grand Rounds, Royal Melbourne Hospital, Melbourne, Australia.

April 2002. 19. Prevention and care of diabetes and its complications. Goulburn Valley Diabetes patient support

group. Shepparton, Australia. July 2002. 20. Diabetes Complications Assessment and Novel Risk Factors. JDRF sponsored satellite

symposium Australian Diabetes Society, Adelaide, September 2002. 21. Vascular Disease Risk Factors in Diabetes. Australian National Medical Research Conference.

Melbourne. November 2002. 22. Diabetic Retinopathy. Directions in Diabetes, Werribee, April 2003. 23. Type 2 diabetes in children. St Vincent’s Hospital Shared Care Program. Richmond. May 2003. 24. Diabetic Retinopathy. Endocrine Rounds, St Vincent's Hospital, July 2003.

Alicia Jenkins 34

25. Diabetes. University program for GPs. Melbourne University, August 2003. 26. Diabetes and its Complications. Southern Inner Community Health Centre Health Professionals

Day. Melbourne, September 2004. 27. Metabolic Syndrome – Latest thinking on triglycerides and HDL. MSD Symposium. Sydney

November 2004. 28. Diabetes for Ultrasonographers. Melbourne, October 2004. 29. Mixed up blood fats in diabetes – techniques to investigate the problem. Clinical Trials Centre,

University of Sydney, February 2005. 30. Diabetes care in Australia and contrasts with the developing world. Diabetes Week Staff

Presentation St. Vincent’s and Mercy Private Hospitals, Melbourne, July 2005. 31. Transition in Type 1 diabetes care. Melbourne Endocrine Interhospital Meeting. RCH August

2005. 32. Diabetes, lipoproteins and vascular damage. Dept. of Physiology and Pharmacology. University

of NSW, August 2005. 33. Microvascular Complications of Diabetes – Bench to Bedside. Annual Meeting Australasian

Microvascular Society. Terrigal, NSW October 2005. Awarded John Lacey Smith Award for Best Presentation of Conference.

34. Risk factors for Diabetic Retinopathy Australian New Zealand College of Ophthalmology,

November 2005. 35. Management of Hyperlipidaemia. GP Conference Melbourne. November 2005 36. Microvascular Complications of Diabetes – Bench to Bedside. Bernie O’Brien Microvascular

Research Institute weekly seminar. November 2005. 37. Hyperlipidaemia investigation and treatment RACP lecture (also webcast). November 2005 38. Vascular disease and novel vascular disease risk factors. Australian Society of Hypertension

December 2005. 39. Treatment of hypertriglyceridaemia. GP forum Shepparton. December 2005. 40. Management of dyslipidaemia, with an emphasis on diabetes. a) Northern GP network. May 2006. b) Western GP network. May 2006. 41. CVD and lipid management in diabetes. Goulburn Valley GP forum. May 2006. 42. New Developments in Diabetes. Keynote speaker Diabetes Week. Shepparton. July 2006

Alicia Jenkins 35

43. AGEs in Diabetes SVH Endocrine unit. Melbourne. July 2006. 44. PEDF in Type 1 diabetes. Oral presentation Australian Diabetes Society Conference. Gold

Coast, Queensland. August 2006. 45. Obesity aggravates diabetes complication risk. Australian Health and Medical Research

Meeting, Melbourne, Australia. November 2006. 46. Diabetes Update. Grand Rounds Goulburn Valley Hospital / Rural Medical School. April 2007 47. Real-Time Glucose Monitoring. Implications for the Safety Critical Worker. Australian Faculty

of Occupational Health Physicians Annual Meeting. Melbourne, May 2007. 48. Diabetes Complication Prediction and Prevention. Northern Hospital. May 2007 49. Diabetes Care Advances in Humans that may be of Benefit to Animals. Keynote speaker.

50. Annual Meeting of Australian Veterinary Science. Gold Coast, Queensland. July 2007. 51. Update on CVD Risk Factor Management Grand Rounds Goulburn Valley Hospital / Rural

Medical School. July 2007 52. Lipoprotein Subfractions by NMR in the FIELD study. FIELD Investigators Meeting. Sydney

December 2007 53. Biomarkers. FIELD Investigators Meeting. Sydney Dec 2007 54. Biomarkers and non-invasive measures of vascular health, tissue AGEs and CGMS. Combined

CCRE Meeting Melbourne and Adelaide. Adelaide February 2008. 55. Markers and Mediators of Diabetes Complications. International Society Resistance Arteries

Annual Meeting. Hamilton Island. February 2008 56. Oxidative Stress in Diabetes. Molecules to Man Seminar Series St. Vincent’s, Melbourne. July

2008 57. Cardiovascular Disease. Know YOUR numbers. Rotary Club Shepparton. August 2008. 58. Poorly controlled Type 1 diabetes. Vic/Tas Endocrine Weekend. Kilmore July 2008.

59. Manuscript writing. Diabetes Unit, Goulburn Valley Base Hospital, Shepparton, August 2008. 60. Glycaemic control targets in diabetes. Endocrine Trainee Program. Australian Diabetes Society

Meeting. Melbourne. August 2008.

61. Combined Hyperlipidaemia in Diabetes Australian Atherosclerosis Society Meeting Masterclass Sydney, November 2008

62. Inflammation in CVD. GP Victorian Program. University of Melbourne. Melbourne, Nov 2008

Alicia Jenkins 36

63. Oxidative Stress, AGEs and Type 1 diabetes Complications. Biomarkers Plenary Speaker. Free

Radical Society Australasia Annual Meeting. Melbourne, Dec. 2008.

64. Algorithms to guide CSII therapy. CCRE meeting. Daylesford. April 2009

65. Teleophthalmology and Telemedicine Potential for Health Care of Indigenous Australians. Melbourne, April 2009.

66. Type 1 diabetes complications – humans and animal models. CTC University of Sydney, May

2009.

67. The Science Behind Insulin Pumps. ADS Meeting, Adelaide, August 2009.

68. NMR dyslipoproteinaemia and gender and the effects of fenofibrate in the FIELD Study. Oral Presentation. ADS Meeting, Adelaide, August 2009.

69. Vascular Physiology of Diabetes: What is different and what we can do about it. Masterclass.

Melbourne November 2009

70. The C word in Type 1 Diabetes. DA Vic. Type 1 in Town Lecture Series. Royal Melbourne Hospital, Melbourne, February 2010.

71. Insulin pumps and real time glucose sensors. Symposium Speaker, Chair and Organizer. World

Internal Medicine Conference, Melbourne, March 2010. 72. Diabetes, the damage that it does. Australian Sonographers Association Conference. Plenary

Lecture. Melbourne, May 2010.

73. Complication Prevention and Care in Type 1 diabetes. DA Vic. Goulburn Valley Health. Shepparton, May 2010.

74. Insulin Pumps and Glucose Sensors. John Turtle Training Course. Australian Diabetes Society

Annual Scientific Meeting. Sydney, Sept, 2010.

75. Biomarkers predict CVD and microvascular complications in the FIELD Study. Masterclass in Vascular Disease in Diabetes. MCG, Melbourne, November 2010.

76. Type 1 Diabetes Complications and Findings from the DCCT Study. Royal Childrens Hospital, Melbourne, November 2010.

77. Biomarkers prediction of micro- and macrovascular complications in the FIELD Study and mechanisms of fenofibrate retinal protection. Victorian Lipid Group. Melbourne, November 2010.

78. Inflammatory and Oxidative Stress Markers Pre- and Post-Islet Cell Transplant. Islet Transplant Consortium Meeting. St. Vincent’s Institute, Melbourne, December 2010.

Alicia Jenkins 37

79. Recurrent severe hypoglycemia in Type 1 diabetes and the potential role of real-time glucose sensing. NDSS. Canberra, Feb 3, 2011.

80. Real-time glucose sensing in Type 1 diabetes and exercise (to GPs and lay audience). HypoActive conference. Melbourne Feb 4-6, 2011.

81. Lipid Trials in Diabetes. Endocrine Society of Australia. Launceston, April 29-May 1, 2011 82. Diabetes Workshop re Insulin Pumps and Fenofibrate Use. GV Base Hospital, Registrar and

Resident Training, Shepparton, May 2011 83. Lipid Trials and Treatments in Diabetes ADS GP Diabetes Day, Melbourne, June, 2011 84. Diabetes in the Elderly, ADS NADC Best Practice in Diabetes Centre, Sydney, July 9, 2011 85. Diabetic Retinopathy: The Endocrinologist’s Perspective. Ophthalmology Weekend.

Melbourne, July 23, 2011 86. Continuous Glucose Monitoring. John Turtle Course. ADS. Perth, Sept. 2011 87. People with Diabetes and Diabetes Devices. ADS/ADEA Perth, Sept. 2011 88. Vascular Dysfunction in Diabetes. ADS. Perth, Sept. 2011

89. Glucose Control and Assessment Devices in Diabetes. Australian Faculty of Occupational

Medicine. Melbourne. Sept. 2011

90. Continuous Glucose Monitoring in Adults. Diabetes Expert Forum (Sanofi-Aventis). Melbourne. October 2011

91. High Throughput Biomarker Analysis. University of Sydney Biomarker Symposium. Sydney.

November 2011.

92. The basic science of fenofibrate and diabetic retinopathy. The 3rd Diabetes and Cardiovascular Disease Masterclass. MCG Melbourne November 2011

93. Telehealth for Diabetes Care. The IBM Challenge. DOER Symposium. University of Melbourne November 2011.

94. The Microvasculature in People with Diabetes Mellitus. The Australian and New Zealand Microvascular Society. Margaret River, Western Australia December 2011

95. Diabetes and the Elderly. ADEA ACT Education Day Canberra, Feb 2012

96. Insulin Pumps – What you need to know now. ADS Endocrine Trainee Inaugural Course

Melbourne March 2012 97. Draft ADS Lipid Guidelines Lilly Meeting Sydney 2012

Alicia Jenkins 38

98. Fenofibrate and Diabetic Retinopathy Sydney 2012

99. Dead in Bed Syndrome. (a) Diabetes Expert Forum. Brisbane July 2012 (b) Diabetes Educators. Bundoora August 2012 (c) Uni. of Melb. Rural Medical School Grand Rounds Oct 2012 (d) Goulburn Valley Health GP meeting October 2012 (e) Melbourne Diabetes Educators December 2012

100. Pumps and Sensors in Type 1 diabetes. Masterclass for Diabetes and Vascular Disease.

Sydney July 2012 101. Draft ADS Lipid Guidelines Masterclass for Diabetes and Vascular Disease. Sydney, July

2012

102. Australia Atherosclerosis Society Masterclass 2012. Residual CVD risk Sydney October 2012

103. The use of technology and remote data management for diabetes care. Melbourne, Nov 2012

104. What has changed over the past 50 years in Type 1 diabetes care. Kellion Medal Award Diabetes Australia Victoria. Nov 2012.

105. Baker IDI Grand Rounds. Continuous Glucose Monitoring for Diabetes December 2012 106. NHMRC Aust. China Meeting. Trials, Tools and Telehealth. Canberra. June 2013

107. Diabetes Australia. Severe hypoglycaemia. DA Melbourne. September 2013

108. Diabetes Complications. Melbourne, September 2013.

International

1. LDL oxidizibility in diabetes mellitus. SouthEastern Lipid Conference, Callaway Gardens, Georgia, USA, September 1994.

2. Update on lipids: Grand Rounds. Medical University of South Carolina, December 1996. 3. Diabetes Research at MUSC. South Carolina Chapter Juvenile Diabetes Foundation Board. June

1998. 4. Diabetes Complication Prevention Research. South Carolina Chapter Juvenile Diabetes Foundation.

July 1998. 5. Lipoproteins and Diabetic Renal Damage. Endocrine Grand Rounds. MUSC. July 1998. 6. Modified Lipoproteins and Vascular Damage. ENGAGE workshop. EASD, Barcelona, Spain,

September 1998. 7. Vascular complications of diabetes - in vivo and in vitro studies. Endocrine Grand Rounds

University of South Carolina, Columbia, USA. August 1999.

Alicia Jenkins 39

8. Lipoproteins and Diabetic Retinopathy. Department of Ophthalmology. MUSC. Feb. 2000. 9. NMR analysis of lipoproteins. Resident’s Grand Rounds. MUSC. Feb. 2000. 10. Controversies in Oxidative Stress and the Role of Vitamin E in Diabetes. American Diabetes

Association. Philadelphia, USA. June 2001. 11. Pulse wave analysis in high vascular disease risk groups. Symposium at American Heart

Association Meeting, Chicago, November 2002. 12. Markers and Mechanisms of Diabetes Complications. Kelly West Memorial Lecture. Medicine

Grand Rounds. University of Oklahoma Health Sciences Center. Oklahoma City, OK, USA. April 2003.

13. Models of Vascular Disease and Diabetes Complications. Endocrine Grand Rounds. University of Oklahoma Health Sciences Center. Oklahoma City, OK, USA. April 2003.

14. Novel tools for vascular disease assessment in diabetes. Diabetes Update Oklahoma Health

Sciences Center, OK, USA. October 2003. 15. Pulse wave analysis in high vascular disease risk groups. Cardiovascular Medicine Grand

Rounds. Oklahoma Health Sciences Center, OK, USA. October 2003. 16. COAT platelets in diabetes. Endocrine Rounds. Oklahoma Health Sciences Center, OK, USA.

October 2003. 17. Inflammation, lipoproteins and Lp(a) in the complications of diabetes. Program Project Advisory

Committee Meeting, Charleston, SC, April 2004. 18. LMW-AGEs in Diabetes. 8th International AGE Meeting. Charleston, SC, Sept. 2004. 19. Diabetes in youth in Australasia. DAWN Youth Program. Copenhagen, Denmark December

2005. 20. Diabetes Care in Australia. Grand Rounds Institute of Endocrinology Tashkent, Uzbekistan.

February 2006. 21. Activities of Insulin For Life. Diabetes in Uzbekistan Conference. Bukkhara, Uzbekistan,

March 2006. 22. Diabetes Screening and Care in Australia. Diabetes in Uzbekistan Conference. Bukkhara,

Uzbekistan, March 2006. 23. Risk markers and mediators of diabetic retinopathy. Diabetes in Uzbekistan Conference.

Bukkhara, Uzbekistan, March 2006. 24. Management of Hyperlipidaemia. Grand Rounds Institute of Endocrinology Tashkent,

Uzbekistan. February 2006.

Alicia Jenkins 40

25. PEDF in Type 1 diabetes. Endocrine Rounds. University of Oklahoma Health Sciences Center, OKC, USA. February 2007.

26. Predictors of diabetes complications. Diabetes Retreat. OUHSC, Oklahoma City, OK, USA 27. Insulin For Life. EASD Amsterdam Sept 2007 28. Insulin For Life. IDF Europe Meeting. Dublin. Sept 2007 29. Type 1 diabetes care update. OUHSC Residents Grand Round Program. Oklahoma City,

Oklahoma, USA, November 2007. 30. The ALGOS Study: Effects of CSII RT-CGM on glycaemia in Type 1 diabetes. Oral

Presentation ADA New Orleans, June 2009. 31. Lipoproteins and adiposity in Type 1 diabetes. Invited Speaker International Society for

Paediatric and Adolescent Diabetes (ISPAD), Slovenia, Sept. 2009

32. Lipoproteins and Type 1 diabetes complications. Paediatric Grand Rounds. OUHSC. Oklahoma City, Oklahoma USA. January 2010.

33. Novel Cardiovascular Risk Factors Predict Cardiovascular Disease in the (Type 2 Diabetes) FIELD Study. American Heart Association, Chicago, November 2010.

34. CSII or MDI for Diabetes Care. American Diabetes Association, San Diego, CA, USA June,

2011 35. Novel Cardiovascular Risk Factors Predict Microvascular and Macrovascular Disease in the

(Type 2 Diabetes) FIELD Study. American Diabetes Association, San Diego, June, 2011

36. Type 1 Diabetes, its complications and technologies for management. Dept. Of Physiology, University of Oklahoma Health Sciences Center. Oklahoma City. Oklahoma, USA. April 2014.

37. Biomarkers in Clinical Trials. Beijing China. Peking University and The George Institute.

October 2015.

38. The prevention of the vascular complications of Type 2 diabetes. Beijing China. Peking University and The George Institute. October 2015.

39. Severe hypoglycaemia and the Dead in Bed Syndrome. Mechanisms and Prevention. Beijing

China. Peking University and The George Institute. October 2015.

40. Mechanisms underlying diabetic retinopathy and treatment targets. Beijing China. Peking University and The George Institute. October 2015.

41. Lipid treatment strategies in diabetes. Beijing China. Peking University and The George

Institute. October 2015.

Alicia Jenkins 41

42. Developing Better Molecular Biomarkers in Obesity. International Congress of Obesity. Kuala Lumpur, Malaysia. March, 2014

43. PEDF and kallistatin in Type 2 diabetes patients (the FIELD Study) OUHSC, Oklahoma City,

OK, April 2014 PUBLICATIONS:

Peer reviewed original research papers

1. Jenkins A, Steele J, Janus E, Best J. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 1991; 40: 787 - 790. 2. Jenkins A, Steele J, Janus E, Santamaria J, Best J. Plasma apolipoprotein(a) is increased in type 2 (non-insulin dependent) diabetic patients with microalbuminuria. Diabetologia 1992; 35: 1055 - 1059. 3. Lee P, Jenkins A, Bourke C, Santamaria J, Paton C, Janus E, Best J. Prothrombotic and antithrombotic factors are elevated in patients with type 1 diabetes complicated by microalbuminuria. Diabetic Medicine 1993; 10: 122 - 128. 4. Jenkins A, Klein R, Chassereau C, Hermayer K, Lopes-Virella M. Susceptibility to in vitro oxidation of LDL from patients with well-controlled IDDM is not increased. Diabetes 1996;45:762-767. 5. Requena JR, Fu M-X, Ahmed MU, Jenkins AJ, Lyons TJ, Thorpe SR Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol, Dial and Transpl. 1996. 11 Suppl 5:48-53. 6. Fu M-X, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, N-(Carboxymethyl)lysine (CML) is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 1996;271:9982-9986. 7. Lyons TJ, Jenkins AJ. Glycation, Oxidation, and Lipoxidation in the Development of the Complications of Diabetes Mellitus: A “Carbonyl Stress” Hypothesis. Diabetes Reviews. 5:365-391,1997. 8. Lyons TJ, Jenkins AJ. Glycated lipoproteins. Cur Opin Lipidology. 8:174-80,1997. 9. Willi SM, O'Rear D, Garvey WT, Colwell JA, Buse M, Jaffa AA, Lopes-Virella MF, Wood D, Mayfield RK, Wallace P, Hermayer KL, Jenkins AJ, Lyons TJ, Mayer-Davis E. Diabetes research in South Carolina: past, present, and future. J South Carolina Med. Assoc. 94:502-508, 1998. 10. Requena JR, Mahtab UA, Fountain CW, Degenhardt TP, Reddy SR, Perez CP, Lyons TJ, Jenkins AJ, Baynes JW, Thorpe SR. Nε-Carboxymethylethanolamine: a biomarker of phospholipid modification by the Maillard reaction in vivo. J. Biol. Chem. 272:17473-9, 1997. 11. Requena JR, Fu M-X, Ahmed MU, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. Quantitation of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human LDL. Biochem. J. 1997; 322:317-325.

Alicia Jenkins 42

12. Jenkins AJ#, Argyropoulos G#, Klein RL, Lyons TJ, Wagenhorst B, J St-Amand, S Marcovina, JJ Albers, PH Pritchard, Garvey WT. Two novel mutations in a compound heterozygous male with familial LCAT deficiency. J. Lipid Research. 1998;38:1870-1876. # Shared first authorship. 13. Fountain WC, Requena JR, Jenkins AJ, Lyons TJ, Smyth B, Baynes JW, Thorpe SR. Quantification of glucitol-ethanolamine and carboxymethylserine: two products of non-enzymatic modification of aminophospholipids formed in vivo. Analytical Biochem, 272:48-55, 1999. 14. Jenkins A, Li W, Moller K, Klein RL, MX Fu, JW Baynes, SR Thorpe, Lyons TJ. Effect of α-tocopherol supplementation on development of toxicity of modified LDL towards retinal capillary cells. Current Eye Res, 19:137-145,1999. 15. Lyons TJ, Li W, Wojciechowski B, Wells-Knecht MC, Wells-Knecht KJ, Jenkins AJ. Aminoguanidine and the effects of modified LDL on cultured retinal capillary cells. Invest Ophthalmol Vis Sci. 41(5):1176-80, 2000. 16. Jenkins AJ, Verlarde V, KC Joyce, KD Phillips, RK Mayfield, TJ Lyons, AJ Jaffa. Native and modified LDL activate ERKinase in mesangial cells. Diabetes. 12:2160-2169, 2000. 17. Jenkins AJ, Lyons TJ. Preventing Vascular Disease in Diabetes. Practical Diabetes, 19:19-32, 2000. 18. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits modification of proteins during lipid peroxidation reactions. J Biol Chem, 275: 21177-84, 2000. 19. Best JD, Jenkins AJ. Novel agents for managing dyslipidaemia. Expert Opin. Investig. Drugs 10 (11), 1-11, 2001. 20. Jenkins AJ*, Velarde V*, Christopher J. Lyons TJ. Jaffa AA. Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells. * equal first author. J App Physiol. 91(3):1412-20, 2001 . 21. Sochaski MA, Jenkins AJ, Lyons TJ, Thorpe SR, Baynes JW. Isotope dilution Gas Chromatography/Mass Spectrometry Method for the Determination of Methionine Sulfoxide in Protein. Analytical Chemistry 73;4662-4667, 2001. 22. Pugh K, Jenkins A, Zheng D, Chinnis S, Hermayer K, Jenkins C. Foot care in diabetes - ideal vs actual practice. South Med J. 2002;98(8):305-10. 23. Cohen J, Jenkins AJ, Karschimkus CS, Qing S, Lee CT, O’Dea K, Best JD, Rowley KG. Paraoxonase activity and other coronary risk factors in a community-based cohort. Redox Report. 2002;7(5):304-7. 24. Rowley K, Walker KZ, Cohen J, Jenkins AJ, O’Neal D, Su Q, Best JD, O’Dea K. Inflammation and vascular endothelial activation in an Aboriginal population: relationships to cardiovascular risk factors and nutritional markers. Med J Aust. 2003;178(10):495-500.

Alicia Jenkins 43

25. Qu S, O’Dea K, Jenkins AJ, Best JD, Rowley K. Low plasma concentrations of diet-derived antioxidants in association with microalbuminuria in Indigenous Australian populations. Clin Sci. 2003 ;105(5) :569-575. 26. O’Neal D, Dragicevic G, Rowley K, Ansari M, Balazs N, Jenkins A, Best J. Association of Type 2 Diabetes and Other Cardiovascular Risk Factors with Intimal Medial Thickness and Pulse Wave Conduction Velocity in Non-stenotic Arteries of Lower Limbs. Diabetic Med. 2003;26(1):99-205. 27. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. The effects of insulin resistance and type 2 diabetes mellitus on lipoprotein subclass size and concentration determined by NMR. Diabetes. 2003;52(2):453-462. 28. Jenkins AJ*, Lyons TJ*, Otvos J, Zheng D, Lackland DT, McGee D, Garvey WT, Klein R, The DCCT/EDIC Research Group. * equal first author. NMR analysis of lipoprotein subclasses in the EDIC cohort: Associations with gender and glycemia. Diabetes Care. 2003;26(3):810-8 29. RL Klein*, SJ Hunter*, AJ Jenkins, D Zheng, AJ Semler, J Clore, WT Garvey, DCCT/EDIC Study Group. * equal first author. Fibrinogen is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of Plasma Fibrinogen and Fibrinogen Gene Polymorphism in the DCCT/EDIC Cohort. Diabetes Care. 2003;26(5):1439-48. 30. Jenkins AJ*, Lyons TJ*, Otvos J, Zheng D, Lackland DT, McGee D, Garvey WT, Klein R, The DCCT/EDIC Research Group. * equal first author. NMR analysis of lipoprotein subclasses in the EDIC cohort: Associations with diabetic nephropathy. Kidney International 2003;64(3):817-28. 31. Meyer C, O'Neal D, Connell W, Alford F, Ward G, Jenkins A. Octreatide in diabetic diarrhoea. Intern Med. J. 2003;33(12)617-618 32. Wong M, Toh L, Wilson A, Karschimkus C, Rowley K, Clemens L, Romas E, Wicks I, McColl G, Best J, Jenkins A. Abnormal elasticity and the relationship to traditional vascular disease risk factors and inflammation in rheumatoid arthritis. Arthritis and Rheumatism 2003;48(1):81-9. 33. Van Doornum S, McColl G, Jenkins A, Green DJ and Wicks IP. Screening For Atherosclerosis In Rheumatoid Arthritis: Comparison Of Two In-Vivo Tests Of Vascular Function. Arthritis and Rheumatism 2003;48(1):72-80. 34. Goodrich JA, Clarkson TB, Swindle MM, Jenkins AJ, Del Signore MJ. Levormeloxifene Effects on Coronary Artery Atherosclerosis and the Uterus of Yucatan Micropigs. Fertil Steril. 2003;79 Suppl 1:779-88. 35. Glare E, Cotton R, Jenkins A. A plastic contaminant masquerades as DNA in mutation detection by denaturing HPLC. Biotechniques. 2003;34(1):59-60. 36. Dudley A, McKinstry W, Thomas D, Best JD, Jenkins AJ. Removal of endotoxin by reverse phase HPLC abolishes anti-endothelial cell activity of bacterially expressed plasminogen kringle 5. Biotechniques 2003; 35(4):724-726. 37. Dudley A, Gilbert RE, Mc Thomas D, Cox A, Price JT, Best J, Jenkins A. STI-571 inhibits in vitro angiogenesis. Biochem Biophys Res Commun. 2003; 310(1):135-142.

Alicia Jenkins 44

38. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27(4):978-83. 39. Jenkins AJ*, Lyons TJ*, Otvos J, Zheng D, Lackland DT, McGee D, Garvey WT, Klein R, The DCCT/EDIC Research Group. * equal first author. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. IOVS. 2004;45:910-918. 40. Wilson A, Prior D, O'Neal D, Best J, Jenkins A. Comparison of non-invasive measures of vascular health. Am. J. Hypertension 2004;17(4):285-91. 41. Jenkins AJ, Thorpe SR, Alderson NL, Hermayer KL, Lyons TJ, King LP, Chassereau C, Klein RL. In vivo glycated LDL is not more susceptible to oxidation than non-glycated LDL in type 1 diabetes. Metabolism 2004; 53(8):969-976. 42. Klein RL*, Hunter SJ*, Le N-A, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ, Garvey WT, DCCT/EDIC Research Group. Apolipoprotein C-III Protein Concentrations and Gene Polymorphisms in Type 1 Diabetes: Associations with Microvascular Disease Complications in the DCCT/EDICT Cohort. Metabolism 2004;53(10):1296-304 43. Lee C, Rowley K, Jenkins A, O'Dea K, Itsiopoulos C, Stoney R, Su Q, Giles G, Best J. Paraoxonase activity in Greek migrants and Anglo-Celtic persons in the Melbourne Collaborative Cohort Study: relationship to dietary markers. European Journal of Nutrition. 2005;44:223-230 44. Klein RL, Hunter SJ, Le N-A, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ, Garvey WT, DCCT/EDIC Research Group. Apolipoprotein C-III Protein Concentrations and NMR profile in Type 1 Diabetes. J. Diabetes and its Complications. 2005 19(1):18-25 45. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp, BE, Neal, BC, Patel, A, MacMahon, W Prediction of heart failure by amino-terminal pro-type natriuretic peptide and C-reactive protein Hypertension 2005;45(1):69-74. 46. Kalogerakis G, Baker A, Christov S, Dwyer K, Dragicevic G, Rowley K, Best JD, Jenkins AJ. Oxidative stress and HDL function in diabetes and renal failure. J Clin Sci. 2005;108(6):497-506. 47. Ryan M, Wilson A, Best JD, Jenkins A Desmond P. Association between liver histology and severity of metabolic syndrome and NAFLD. Diabetes Care 2005;28(5):1222-4. 48. Gome J, Bala N, Ward G, Jenkins A. Diabetes in the young – not always as it seems. Int. Med J. 2005;35(5):309-10. 49. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp, BE, Neal, BC, Patel, A, MacMahon W. Prediction of myocardial infarction by amino-terminal pro-type natriuretic peptide and inflammation markers in pervious stroke patients. Circulation 2005; 112(1):110-6. 50. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM Effect of intensive glycemic control on levels of markers of inflammation in the diabetes control and complications trial. Circulation 2005;111(19):2446-53.

Alicia Jenkins 45

51. Dudley AC, Thomas D, Best J, Jenkins A. A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochem J. 2005 May 27; [Epub ahead of print] 52. Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW. Chemical modification of proteins during peroxidation of phospholipids. J Lipid Res. 2005;46(7):1440-9. 53. Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, Neal BC, Patel A, Jenkins AJ, Kemp BE, MacMahon SW. Associations of inflammatory and haemostatic variables with the risk of recurrent stroke. Stroke 2005;36(10):2143-7. 54. Nelson C, Karschimkus C, Rowley K, O’Neal D, Wilson A, Packham D, Becker G, Best J, Jenkins A. Inflammation in early IgA and diabetic nephropathy. Neph., Dial Transpl. 2005; 20(11):2420-6 55. McLachlan KA, O’Neal D, Jenkins AJ, Alford F. Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metabolism Research and Reviews 2006,22 (2):131-138. 56. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW. Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. Arch Neurol. 2006;63(1):60-5. 57. Jenkins AJ*, Lyons TJ*, Zheng D, Otvos JD, Klein RL, Lackland DT, McGee D, Garvey WT, and The DCCT/EDIC Research Group. *Equal first author. NMR-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-medial thickness. Diabetic Medicine 2006;23(9):955-66. 58. Lee A, Godfrey T, Rowley K, Karschimkus C, Dragicevic G, Romas E, Clemens L, Wilson A, Nikpour M, Prior D, Best J, Jenkins A. Adverse risk factor profile in stable mild SLE. Int Med J 2006; 36(4):237-243. 59. Mason NJ, Jenkins AJ, Best JD, Rowley KG. Exercise frequency and arterial compliance in non-diabetic and Type 1 diabetic subjects. Eur J Cardiovasc Prev Rehabil. 2006;13(4):598-603. 60. LM Wilson, PF James, A Jenkins, JD Wade, AF Hill, MA Perugini, GJ Howlett. High density lipoproteins bind Abeta and apolipoprotein C-II amyloid fibrils. J. of Lipid Research 2006;47(4):755-60. 61. Alibrahim E, Donaghue KC, Rogers S, Hing S, Jenkins AJ, Chan A, Wong TY. Retinal Vascular Caliber and Risk of Retinopathy in Type 1 Diabetes Mellitus. Ophthalmology. 2006;113(9):1499-503. 62. Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, Silink M, Donaghue KC. Association between PON 1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications. 2006;20(5):322-8.

Alicia Jenkins 46

63. Yu J, Thorpe SR, Jenkins AJ, Shaw JN, Sochaski MA, McGee D, Aston CE, Orchard TJ, Silvers N, Peng YG, McKnight AJ, Baynes JW, Lyons TJ, The DCCT/EDIC Research Group. Advanced Glycoxidation End-Products and Methionine Sulfoxide in Skin Collagen in Type 1 Diabetes. Diabetologia 2006;49(10):2488-98. 64. Wilson AM, Swan JD, Ding H, Zhang Y, Whitbourn RJ, Gurry J, Yii M, WilsonAC, Hill M, Triggle C, Best JD, Jenkins AJ. Widespread vascular production of C-reactive protein (CRP) and a relationship between serum CRP, plaque CRP and intimal hypertrophy. Atherosclerosis. 2007;191(1):175-81. 65. Shemesh T, Rowley KG, Jenkins A, Brimblecombe J, Best JD, O'Dea K. Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeast Arnhem Land of Australia. Int J Obes (Lond). 2007;31(3):564. 66. Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G; The DCCT/EDIC Research Group. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007;190(2):359-69. 67. Choo KE, Lau KB, Davis WA, Chew PH, Jenkins AJ, Davis TM. Effects of diabetic parentage on cardiovascular risk factors in pre-pubertal Malay children. Diabetes Research and Clinical Practice 2007; 76(1):119-125 68. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye K-A. The Impact of Glycation on Apolipoprotein A-I Structure and its Ability to Activate Lecithin:Cholesterol Acyltransferase Diabetologia. 2007;50(3):643-53. 69. Campbell DJ, Woodward M, Chalmers JO, Colman SA, Jenkins AJ, Kemp B, Neal BC. Low Density Lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. Eur. J. of Cardiovascular Prevention and Rehabilitation. 2007 14(3):413-8. 70. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW. Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. J Hypertens. 2007;25(3):699-705. 71. Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci. 2007; 333(6):333-9. 72. McLachlan K, Jenkins A, O’Neal D. The Role of Continuous Glucose Monitoring in Clinical Decision Making in Diabetes. ANZ J Ob and Gynae. Aust N Z J Obstet Gynaecol. 2007;47(3):186-90. 73. Jenkins AJ*, Zhang SX*, Rowley KG, Karschimkus CS, Nelson C, Chung SJ, O'Neal D, Harper CA, Januszewski AS, Croft KD, Mori TA, Lyons TJ, Best JD, Ma JX. Increased Serum PEDF is Associated With Microvascular Complications, Vascular Stiffness, and Inflammation in Type 1 Diabetes. * equal 1st author Diabetic Medicine 2007;24(12):1345-51.

Alicia Jenkins 47

74. Y Yu, Wei Li, B Wojciechowski, AJ. Jenkins, TJ. Lyons. Effects of D- and L-Glucose and Mannitol on Retinal Capillary Cells: Inhibition by Nanomolar Aminoguanidine. American Journal of Pharmacology and Toxicology. In press 2007. 75. Shemesh T et al. Low HDL-cholesterol is the most prevalent metabolic abnormality for Australian Aboriginal People of either gender and across BMI strata. European Journal of Cardiovascular Prevention and Rehabilitation. In press 2007 76. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, Lyons TJ, Garvey WT, Virella G; the DCCT/EDIC Study Group. Risk Factors related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and their Relationship with Nephropathy and Macrovascular Complications. Diabetes Care 2008 Jul 15. 77. O'Neal DN, Piers LS, Iser DM, Rowley KG, Jenkins AJ, Best JD, O'Dea K. Australian Aboriginal people and Torres Strait Islanders have an atherogenic lipid profile that is characterised by low HDL-cholesterol level and small LDL particles. Atherosclerosis 2008: 201(2):368-377. 78. Jenkins AJ, Gosmanova AK, Lyons TJ, May KD, Dashti A, Baker MZ, Olansky L, Aston CE, Dale GL. Coated-platelet levels in patients with Type 1 and with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;81(2):e8-10. 79. Gallego PH, Craig ME, Duffin AC, Bennetts B, Jenkins AJ, Hofer S, Lam A, Donaghue KC. Association between p.Leu54Met polymorphism at the paraoxonase-1 gene and plantar fascia thickness in young subjects with type 1 diabetes. Diabetes Care. 2008;31(8):1585-9. 80. Jenkins AJ, Rothen M, Klein RL, Moller K, Eldridge L, Zheng D, Durazo-Arvizu R, McGee D, Lackland D, Thorpe SR, Garvey WT, Lyons TJ; DCCT/EDIC Research Group. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications. 2008;22(3):153-63. 81. Januszewski AS, Thomas MC, Karschimkus CS, Chung JS, Rowley KG, Nelson CL, O'Neal DN, Dragicevic G, Harper CA, Best JD, Jenkins AJ. Longitudinal analysis of low-molecular weight fluorophores in type 1 diabetes mellitus. J Med Invest. 2008;55(1-2):29-36. 82. Hoffmann P, Woon J, Rowley KG, Karschimkus C, Nelson CL, Dragicevic G, O'Neal D, Wilson A, Croft KD, Mori TA, Kemp BE, Best JD, Jenkins AJ. Glutathionyl haemoglobin is not increased in diabetes nor related to glycaemia, complications, dyslipidaemia, inflammation or other measures of oxidative stress. Diabetes Res Clin Pract. 2008;80(2):e1-3. 83. Rowley KG, O'Dea K, Anderson I, McDermott R, Saraswati K, Tilmouth R, Roberts I, Fitz J, Wang Z, Jenkins A, Best JD, Wang Z, Brown A. Lower than expected morbidity and mortality for an Australian Aboriginal population: 10-year follow-up in a decentralised community. Med J Aust. 2008;188(5):283-7. 84. Brazionis L, Rowley K, Jenkins A, Itsiopoulos C, O'Dea K. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy. Arterioscler Thromb Vasc Biol. 2008;28(4):786-91.

Alicia Jenkins 48

85. Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE; DCCT/EDIC Research Group, Thorpe SR, Baynes JW. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res. 2008;49(4):847-55. 86. Jenkins AJ, Zhang SXn Gosmanova A, Aston CE, Dashti A, Baker MZ, Lyons TJ, Ma J-x. Increased serum PEDF levels in Type 2 diabetes patients. Diabetes Res and Clin Prac. 2008;82(1)e5-7 87. Cheung N, Rogers SL, Donaghue KC, Jenkins AJ, Tikellis G, Wong TY. Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes Care. 2008;31(9):1842-6. 88. N Cheung, KC Donaghue, G Liew, JJ Wang, SW Lim, AJ Jenkins, W Hsu, ML Lee, TY Wong. Fractal Dimension of the Retinal Vascular Network and Retinopathy in Type 1 Diabetes. Diabetes Care 2009;32(1):106-110. 89. ZS Valaydon, P Lee, GL Dale, AS Januszewski, KG Rowley, H Nandukar, JD Best,TJ Lyons, AJ Jenkins. Increased Coated-Platelet Levels in End Stage Renal Disease Patients. Nephrology 2009;14(2):148-154 90. Hodge A, Jenkins, A, English D, O’Dea, K, Giles Graham G. NMR-determined lipoprotein subclass profile predicts Type 2 diabetes. Diabetes Research and Clinical Practice. 2009:83(1):132-139 91. T Shemesh, K Rowley, AJ Jenkins, JD Best, K O'Dea C-reactive protein levels are very high and more stable over time than the traditional vascular risk factors total cholesterol and systolic blood pressure in an Australian Aboriginal cohort. Clinical Chemistry 2009;55(2):336-341. 92. Y Yu, AJ Jenkins, AJ Nankervis, K Hanssen, H Scholz, T Henriksen, B Lorentzen, T Clausen, SK Garg, MK Menard, SM Hammad, JC Scardo, JR Stanley, A Dashti, K May, K Lu, CE Aston, J Wang, SX Zhang, Jx Ma, TJ Lyons. Anti-angiogenic factors and preeclampsia in Type 1 diabetes. Diabetologia 2009;52(1):160-168. 93. AJ Kreis, JJ Wang, FM A Islam, R Klein, BEK Klein, MF Cotch, AR Sharrett, A Jenkins, S Shea, TY Wong. Nuclear Magnetic Resonance Lipoprotein Subclass and Diabetic Retinopathy: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes and Vascular Disease Research 2009;6(1):40-42 94. S Chen, A Jenkins, H Margolius. Elevated prostaglandins and monocyte acetylated histone in Type 1 diabetes patients. Diabetic Medicine 2009;26(2):182-186 95. Luke J, Brown A, O’Neal D, O’Dea K, Jenkins A, Kelaher M, Best J, Rowley K. Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Medical Journal of Australia. 2009; 190(10):552-556. 96. Cheung NW, Conn JD, d'Emben JC, Gunton JE, Jenkins AJ, Ross GP, Singha AK, Adrikopoulos S, Colagouri S, Twigg SM. Position Statement of the Australian Diabetes Society: individualisation of glycated haemoglobin tares for adults with diabetes mellitus. Medical Jounrnal of Australia. 2009 191(6):339-344.

Alicia Jenkins 49

97. Vethakkan SR, Jenkins AJ, Kay TWH, Goodman DJ, Walters JM, Gooley JL, Boston RC, Holmes-Walker DJ, Ward GM: Improved 2nd phase insulin secretion and preserved insulin sensitivity following islet transplantation. Transplantation In press:accepted Dec, 2009 98. Lim, SW, Cheung N, Wang JJ, Donaghue K, Liew G, Islam F M, Jenkins A, Wong T. Retinal Vascular Fractal Dimension and Risk of Early Diabetic Retinopathy: A Prospective Study of Children and Adolescents with Type 1 Diabetes. Diabetes Care 2009; 32(11):2081-2083 99. Campbell DJ, Kladis A, Zhang Y, Jenkins AJ, Yii M, Kenny JF, Kelly DJ. Increased tissue kallikrein expression in type 2 diabetes. Diabetologia 2010; 53(4):779-785. 100. Brazionis L, Yau J, Itsiopoulos C, O’Dea K, Wong T, Jenkins AJ. PAI-1 activity and retinal vascular calibre in type 2 diabetes. Diab Res Clin Prac. 2010;87(2):192-199 101. Griffin M, Wilson A, Mok YF, Januszewski AS, Wilson AM, Karschimkus C, Romas E, Lee AB, Godfrey T, Wong M, Clemens L, Jenkins AJ, Howlett G. Thioflavin T fluorescence in human serum: Correlations with vascular health and cardiovascular risk factors. Clinical Biochemistry 2010; 43(3):278-286 102. Nobecourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins AJ, Dusting GJ, Bonnet DJ, Curtiss LK, Barter PJ, Rye K-R. Non-Enzymatic Glycation Impairs the Anti-Inflammatory Properties of Apolipoprotein A-I. Atherosclerosis, Thrombosis and Vascular Biology. 2010; 30(4)766-772 103. Jenkins AJ, Krishnamurthy B, Colman P, Rodda C, Cameron F, O’Connell M, Teede H, Hamblin S, Best JD, O’Neal D. Evaluation of an Algorithm to Guide Patients with Type I Diabetes Treated with Continuous Subcutaneous Insulin Infusion (CSII) on How to Respond to Real-Time Continuous Glucose Levels- A Randomised Control Trial. The ALGOS Study. Diabetes Care 2010; 33(6):1242-1248 104. Sasongko MB, Wang J, Donaghue KC, Cheung N, Benitez-Aguirre P, Jenkins A, Hsu W, Lee M-L, Wong TY. Alterations in Retinal Microvascular Geometry in Young Type 1 Diabetes. Diabetes Care 2010; 33(6):1331-1336. 105. Chan DC, Hamilton SJ, Rye KA, Chew GT, Jenkins AJ, Lambert G, Watts GF. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab. 2010;12(9):752-6. 106. Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, Kenny JF, Newcomb AE, Kelly DJ, Black MJ. Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease. Hypertension. 2011;57(2):186-92 107. Beauchamp A, Tonkin A, Peeters A, Wolfe R, Turrell G, Harriss L, Giles GG, English DR, Jenkins AJ. Associations among smoking status, lifestyle and lipoprotein subclasses. J Clin Lipidol. 2010;4(6):522-30.

Alicia Jenkins 50

108. Hodge AM, Jenkins AJ, English DR, O'Dea K, Giles GG. NMR-determined lipoprotein subclass profile is associated with dietary composition and body size. Nutr Metab Cardiovasc Dis. 2010 Nov 15. [Epub ahead of print] 109. Jenkins AJ, McBride JD, Januszewski AS, Karschimkus CS, Zhang B, O'Neal DN, Nelson CL, Chung JS, Harper CA, Lyons TJ, Ma JX. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res. 2010;2:19. 110. Klein RL, Carter RE, Jenkins AJ, Lyons TJ, Baker NL, Gilbert GE, Virella G,Lopes-Virella MF; the DCCT/EDIC Research Group. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2010 Jun 2. [Epub ahead of print] 111. Vethakkan SR, Jenkins AJ, Kay TW, Goodman DJ, Walters JM, Gooley JL, Boston RC, Holmes-Walker DJ, Ward GM. Improved second phase insulin secretion and preserved insulin sensitivity after islet transplantation. Transplantation. 2010;89(10):1291-3 112. Sasongko MB, Wang JJ, Donaghue KC, Cheung N, Benitez-Aguirre P, Jenkins A, Hsu W, Lee ML, Wong TY. Alterations in retinal microvascular geometry in young type 1 diabetes. Diabetes Care. 2010;33(6):1331-6. 113. Nobécourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins AJ, Dusting GJ, Bonnet DJ, Curtiss LK, Barter PJ, Rye KA. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2010;30(4):766-72. 114. Beauchamp A; Tonkin A; Peeters A; Wolfe R; Turrell G; Harriss L; Otvos JD; Giles GG; English DR; Jenkins AJ. Associations among smoking status, lifestyle and lipoprotein subclasses. J Clin Lipidology 2010;4(6):522-30. 115. Benitez-Aguirre P, Craig ME, Sasongko MB, Jenkins AJ, Wong TY, Wang JJ,Cheung N, Donaghue KC. Retinal vascular geometry predicts incident retinopathy in young people with type 1 diabetes: a prospective cohort study from adolescence. Diabetes Care. 2011 Jul;34(7):1622-7. PubMed PMID: 21593293;PubMed Central PMCID: PMC3120178. 116. Azar M, Basu A, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T,Garg SK, Hammad SM, Scardo JA, Aston CE, Lyons TJ. Serum carotenoids and fat-soluble vitamins in women with type 1 diabetes and preeclampsia: a longitudinal study. Diabetes Care. 2011 Jun;34(6):1258-64.PubMed PMID: 21498785; PubMed Central PMCID: PMC3114346. 117. B.E. Brown, E. Nobecourt, J. Zeng, A.J. Jenkins, K.-A. Rye, M.J. Davies. Late but not early glycation of ApoA1 impairs cholesterol efflux from lipid-laden macrophages. Atheroslcerosis In press 2010. 118. Boyle AJ, Yeghiazarians Y, Shih H, Hwang J, Ye J, Sievers R, Zheng D, Palasubramaniam J, Palasubramaniam D, Karschimkus C, Whitbourn R, Jenkins A,Wilson AM. Myocardial production and

Alicia Jenkins 51

release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man. J Transl Med. 2011 Sep 12;9:150. PubMed PMID: 21910857; PubMed Central PMCID: PMC3180393. 119. B. Rasmussen, G.Ward, A Jenkins, S.J. King, P Dunning. How young adults with Type 1 diabetes manage life transitions. J. Clinical Nursing. 2011;20(13-14):1981-1992. 120. Jenkins AJ, Krishnamurthy B, Colman P, Rodda C, Cameron F, O’Connell M, Teede H, Hamblin S, Best JD, O’Neal D. An Algorithm Guiding Responses to Real-Time Continuous Glucose Monitoring Improves Quality of Life. Diabetes Technologies and Therapeutics 2011;13(2):105-9. 121. M Bayu Sasongko, TY Wong, TT Nguyen, R Kawasaki, A Jenkins, J Shaw, JJ Wang. Serum Apolipoprotein AI and B are Stronger Predictors of Diabetic Retinopathy than Traditional Lipids. Diabetes Care. 2011 ;34(2):474-9. 122. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; on behalf of the FIELD Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011 ;54(2):280-290. 123. F Tabet, G Lambert, LF C Torres, L Hou, I Sotirchos, RM Touyz, AJ Jenkins, PJ Barter, K-A Rye Lipid-free apolipoprotein A-I and discoidal reconstituted HDL differentially inhibit glucose-induced oxidative stress in human macrophages. Atherosclerosis, Thrombosis and Vascular Biology. 2011;31(5):1192-200. 124. M Azar*, A Basu*, AJ Jenkins, AJ. Nankervis, KF Hanssen, H Scholz, T Henriksen, SK Garg, SM. Hammad, JC Scardo, CE. Aston, TJ. Lyons. Serum Carotenoids and Fat-Soluble Vitamins in Women with Type 1 Diabetes and Pre-Eclampsia: a Longitudinal Study. Diabetes Care. 2011 Jun;34(6):1258-64. * equal first author 125. Khoo J, Piantadosi C, Duncan R, Worthley S, Jenkins A, Noakes M, Worthley M, Lange K, Wittert G. Comparing Effects of a Low-energy Diet and a High-protein Low-fat Diet on Sexual and Endothelial Function, Urinary Tract Symptoms and Inflammation in Obese Diabetic Men. J Sex. Med. 2011;8(10):2868-75. 126. MB Sasongko, TY Wong, KC Donaghue, N Cheung, AJ Jenkins, P Benitez-Aguirre, JJ Wang. Retinal Arteriolar Tortuosity is Associated with Diabetic Retinopathy and Early Kidney Dysfunction in Type 1 Diabetes. American J. of Ophthalmology 2011 153(1):176-83 127. Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, Kenny JF, Newcomb AE, Schalkwijk CG, Black MJ Kelly DJ. Impact of Type 2 diabetes and the metabolic structure and microvasculature of men with coronary artery disease. Cardiovascular Diabetology. 2011 19;10:80

Alicia Jenkins 52

128. Yu Y, Hanssen K, Kalyanaraman V, Chirindel A, Jenkins A, Nankervis A, Torjesen P, Scholz H, Henriksen T, Lorentzen B, Garg S, Menard M, Hammad S, Scardo J,Stanley J, Wu M, Basu A, Aston C, Lyons T. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes. BJOG. 2012 Aug 20. doi: 10.1111/j.1471-0528.2012.03463.x. [Epub ahead of print] PubMed PMID: 22900949. 129. AS Januszewski, N Sachithanandan, C Karschimkus, DN. O'Neal, CK Yeung, N Alkatib, AJ Jenkins. Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and relate to vascular stiffness. Diabetic Medicine. 2012;29(6):726-33

130. Benitez-Aguirre PZ, Craig ME, Jenkins AJ, Gallego PH, Cusumano J, Duffin AC,Hing S, Donaghue KC. Plantar fascia thickness is longitudinally associated with retinopathy and renal dysfunction: a prospective study from adolescence to adulthood. J Diabetes Sci Technol. 2012 1;6(2):348-55. 131. Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G; DCCT/EDIC Study Group. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012 ;35(6):1333-40. 132. Sasongko MB, Wong TY, Nguyen TT, Kawasaki R, Jenkins AJ, Shaw J, Robinson C,Wang JJ. Serum apolipoproteins are associated with systemic and retinal microvascular function in people with diabetes. Diabetes. 2012 Jul;61(7):1785-92. 133. Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, Kenny JF, Newcomb AE,Kelly DJ, Black MJ. Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. Int J Cardiol. 2012 Mar 27. [Epub ahead of print] PubMed PMID: 22459379. 134. Basu A, Alaupovic P, Wu M, Jenkins AJ, Yu Y, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, Lorentzen B, Clausen T, Garg SK, Menard MK, Hammad SM, Scardo JA,Stanley JR, Dashti A, Aston CE, Lyons TJ. Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study. J Clin Endocrinol Metab. 2012 May;97(5):1752-62. 135. Benitez-Aguirre PZ, Sasongko MB, Craig ME, Jenkins AJ, Cusumano J, Cheung N,Wong TY, Donaghue KC. Retinal vascular geometry predicts incident renal dysfunction in young people with type 1 diabetes. Diabetes Care. 2012 Mar;35(3):599-604. 136. Januszewski AS, Sachithanandan N, Karschimkus C, O'Neal DN, Yeung CK, Alkatib N, Jenkins AJ. Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med. 2012 Jun;29(6):726-33.

Alicia Jenkins 53

137. Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K; FIELD Study Investigators. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012 Feb;35(2):218-25. 138. Sasongko MB, Wong TY, Nguyen TT, Shaw JE, Jenkins AJ, Wang JJ. Novel versus traditional risk markers for diabetic retinopathy. Diabetologia. 2012 Mar;55(3):666-70. 139. Januszewski AS, Karschimkus C, Davis KE, O'Neal D, Ward G, Jenkins AJ. Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Res Clin Pract. 2012 Jan;95(1):e17-9. 140. Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, Kenny JF, Newcomb AE, Schalkwijk CG, Black MJ, Kelly DJ. Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc Diabetol. 2011 Sep 19;10:80. 141. Sasongko MB, Wong TY, Donaghue KC, Cheung N, Jenkins AJ, Benitez-Aguirre P,Wang JJ. Retinal arteriolar tortuosity is associated with retinopathy and early kidney dysfunction in type 1 diabetes. Am J Ophthalmol. 2012 Jan;153(1):176-83.e1.

142. Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, Kenny JF, Newcomb AE, Schalkwijk CG, Black MJ, Kelly DJ. Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels. Plos One. 2012;7(11):e49813.

143. Ong KL, Rye KA, O'Connell R, Jenkins AJ, Brown C, Xu A, Sullivan DR, Barter PJ, Keech AC; on behalf of the FIELD study investigators. Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. J Clin Endocrinol Metab. 2012;97(12):4701-4708. 144. Vethakkan SR, Walters JM, Gooley JL, Boston RC, Kay TW, Goodman DJ, Jenkins AJ, Ward GM. Normalized NEFA dynamics during an OGTT after islet transplantation. Transplantation. 2012;94(7):e49-51. 145. Yu Y, Hanssen K, Kalyanaraman V, Chirindel A, Jenkins AJ, Nankervis AJ, Torjesen P, Scholz H, Henriksen T, Lorentzen B, Garg S, Menard M, Hammad SM,Scardo J, Stanley J, Wu M, Basu A, Aston C, Lyons TJ. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes. BJOG. 2012;119(12):1512-20.

Alicia Jenkins 54

146. DN O’Neal, S Adhya, A Jenkins, G Ward, JB Welsh, Gayane Voskanyan. Feasibility of Adjacent Insulin Infusion and Continuous Glucose Monitoring (CGM) via the Medtronic Combo-set. J. Diabetes Science and Technology. J Diabetes Sci Technol. 2013 Mar 1;7(2):381-8.

147. M Du, A Basu, D Fu, M Wu, M Centola, AJ Jenkins, KF Hanssen, SK. Garg, SM Hammad, JA Scardo, CE Aston, TJ Lyons. Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study. Diabetes Care. Diabetes Care. 2013 Jul;36(7):2054-61.

148. Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott R, Lyons TJ, Ma JX. Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. Diabetes. 2013 Jan;62(1):261-72. 149. Samaras K, Viardot A, Lee PN, Jenkins A, Botelho NK, Bakopanos A, Lord RV, Hayward CS. Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: The role of immune cell activation and insulin resistance. Diab Vasc Dis Res. 2013 Jan;10(1):40-8. 150. Naser N, Januszewski AS, Brown BE, Jenkins AJ, Hill MA, Murphy TV. Advanced glycation end products acutely impair Ca(2+) signaling in bovine aortic endothelial cells. Front Physiol. 2013;4:38. Epub 2013 Mar 11. PubMed PMID: 23483845; PubMed Central PMCID: PMC3593230. 151. Luke J, Brown A, Daniel M, O’Dea K, Best JD, Jenkins A, Wang Z, McDermott R, Wang Z, Rowley K. The metabolic syndrome and CVD outcomes for a central Australian cohort. Diabetes Research and Clinical Practice. 2013 Jun;100(3):e70-3. doi:10.1016/j.diabres.2013.03.020. Epub 2013 Mar 26. PubMed PMID: 23540681 152. Azar M, Lyons TJ, Alaupovic P, Stoner JA, Quiroga C, Kaufman DG, Lopes-Virella M, Klein RL, VADT Study Group, Jenkins AJ,. Apolipoprotein-Defined and NMR Lipoprotein Subclasses in the Veterans Affairs Diabetes Trial. J. of Diabetes and its Complications. 2013 Nov-Dec;27(6):627-32. doi: 10.1016/j.jdiacomp.2013.05.005.Epub 2013 Aug 1. PubMed PMID: 23911536. 153. SE Bursell, AJ Jenkins, L Brazionis, K Rowley, Brown A. Telehealth in Australia – An evolution in health-care services. Letter to the Editor. Medical Journal of Australia. 2013 Jun;100(3):e70-3. doi:10.1016/j.diabres.2013.03.020. Epub 2013 Mar 26. PubMed PMID: 23540681. 154. Grant JF, Martin SA, Taylor AW, Wilson DH, Araujo A, Adams RJ, Jenkins A, Milne RW, Hugo GJ, Atlantis E, Wittert GA. Cohort Profile: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) Study. Int J Epidemiol. 2013 Jun 19. [Epub ahead of print] PubMed PMID: 23785097. 155. Brown BE, Nobecourt E, Zeng J, Jenkins AJ, Rye KA, Davies MJ. Apolipoprotein A-I glycation by Glucose and Reactive Aldehydes Alters Phospholipid Affinity but Not Cholesterol Export from Lipid-Laden Macrophages. PLoS One. 2013 May 31;8(5):e65430. 156. Samaras K, Viardot A, Botelho NK, Jenkins A, Lord RV. Immune cell-mediated inflammation and the early improvements in glucose metabolism after gastric banding surgery. Diabetologia. 2013 Dec;56(12):2564-72. doi: 10.1007/s00125-013-3033-7. Epub 2013 Sep 13. PubMed PMID: 24114113.

Alicia Jenkins 55

157. Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes-Virella M, Baker NL, Hunt KJ, Lackland DT, Garvey WT, Lyons TJ; DCCT/EDIC Research Group. Apolipoprotein-defined lipoproteins and apolipoproteins: Associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications. 2013 Jul 11. doi:pii: S1056-8727(13)00128-1. 158. Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013 Dec;231(2):315-22. doi:10.1016/j.atherosclerosis.2013.09.027. Epub 2013 Oct 11. PubMed PMID: 24267245. 159. Kaidonis G, Abhary S, Daniell M, Gillies M, Fogarty R, Petrovsky N, Jenkins A, Essex R, Chang JH, Pal B, Hewitt AW, Burdon KP, Craig JE. Genetic study of Diabetic Retinopathy: Recruitment methodology and analysis of baseline characteristics. Clin Experiment Ophthalmol. 2013 Sep 30. doi: 10.1111/ceo.12239. [Epub ahead of print] PubMed PMID: 24112246. 160. Grant JF, Martin SA, Taylor AW, Wilson DH, Araujo A, Adams RJ, Jenkins A, Milne RW, Hugo GJ, Atlantis E, Wittert GA. Cohort Profile: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) Study. Int J Epidemiol. 2013 Jun 19. [Epub ahead of print] PubMed PMID: 23785097. 161. O'Connell PJ, Holmes-Walker DJ, Goodman D, Hawthorne WJ, Loudovaris T, Gunton JE, Thomas HE, Grey ST, Drogemuller CJ, Ward GM, Torpy DJ, Coates PT, Kay TW; Australian Islet Transplant Consortium. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. Am J Transplant. 2013 Jul;13(7):1850-8. 162. Rasmussen B, Hendrieckx C, Clarke B, Botti M, Dunning T, Jenkins A, Speight J. Psychosocial issues of women with type 1 diabetes transitioning to motherhood: a structured literature review. BMC Pregnancy Childbirth. 2013 Nov 23;13:218. doi: 10.1186/1471-2393-13-218. PubMed PMID: 24267919. 163. Bursell SE, Jenkins AJ, Brazionis L, Rowley KG, Brown AD. Telehealth in Australia: an evolution in health care services. Med J Aust. 2013 Jul8;199(1):23-4. PubMed PMID: 23829251. 164. Jenkins AJ, Fu DongXu, Azar M, Stoner JS, Kaufman DG, Zhang S, Klein RL, Lopes-Virella MF, Ma JX, Lyons TJ, VADT investigators. Clinical Correlates of Serum Pigment Epithelium-Derived Factor in Type 2 Diabetes Patients. J. Diabetes Complications. In press 2014. 165. McBride J, Jenkins A, Xiaochen L, Zhang B, Lee K, Berry WL, Janknecht R, Griffin C, Aston CE, Lyons T, Tomasek JJ, Ma JX. Elevated Circulation Levels of an Anti-angiogenic SERPIN Impairs Wound Healing through Suppression of Wnt Signaling. J Investigative Dermatology. In press 2014. 166. Hendrieckx C, Halliday JA, Bowden JP, Colman PG, Cohen N, Jenkins A, Speight J. Severe hypoglycaemia and its association with psychological well-being in Australian adults with type 1 diabetes attending specialist tertiary clinics. Diabetes Research and Clinical Practice. Online Jan 8, 2014.

Alicia Jenkins 56

167. Vethakkan SR, Walters JM, Gooley JL, Boston RC, Kay TW, Goodman DJ, Jenkins AJ, Ward GM. The incretin response after successful islet transplantation. Transplantation. 2014 Jan 27;97(2):e9-e11.

168. Jenkins A. Sometimes you have to give a man a fish. MJA In press 2014

169. SSAO activity

DCCT EDIC related papers – listed but not as a named author 1. Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, Zinman B; DCCT/EDIC Research Group. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 2013 Dec;62(12):3976-86. doi:10.2337/db13-1093. PubMed PMID: 24264395; PubMed Central PMCID: PMC3837056.

Reviews

1. Jenkins A, Best J. The role of lipoprotein (a) in the vascular complications of diabetes mellitus.

J Int Med 1995:237:359-365. 2. Stitt A, Jenkins A, Cooper M. AGEs and the complications of diabetes. Expert Opin.

Investig. Drugs. 2002;11(9):1205-23. 3. Jenkins AJ, Garvey WT, Klein RL. Lipoproteins in Type 1 Diabetes. Current Opinion in

Endocrinology and Diabetes. 2004. 4. Jenkins A, Klein R, Lyons T, Best J. Glycoxidation, Lipoproteins and Diabetic Angiopathy.

Diabetes Metab Res Rev. 2004;20(5):349-68 5. Jenkins AJ, Rowley K, Lyons TJ, Hill MJ, Best JD, Klein RL. Lipoproteins and diabetic

microvascular complications. Curr Pharm Design. 2004, 10, 3395-3418. 6. Dudley AC, Thomas D, Best J, Jenkins A. The STATS in cell stress-type responses. Cell

Commun Signal. 6;2(1):8. 2004 7. Andrews KL, Pannirselvam M, Anderson TJ, Jenkins AJ, Triggle CR, Hill MA. The vascular

endothelium in diabetes: A practical target for drug treatment? Expert Opinions in Theraputic Targets. 2005;9(1):101-17.

8. Bennett CM, Jenkins AJ, Guo M, Dharmage SC. Will global standardizsation of test reporting

make HbA1c the preferred diabetes screening test? Endocrine Reviews 2007. 9. Yau J, Lee P, Wong T, Best JD, Jenkins AJ. Cardiovascular and Thrombophilic

Risk Factors Associated with Retinal Vein Occlusion. Internal Medicine Journal. 2008;38(12):904-910.

Alicia Jenkins 57

10. Yau J, Lee P, Wilson A, Jenkins AJ. Metal Prosthetic Valve Endocarditis. Evidence for anticoagulation. Internal Medicine Journal. In press June 2010.

11. Ford PJ, Raphael SL, Cullinan MP, Jenkins AJ, West MJ, Seymour GJ. Why should a doctor be

interested in oral disease? Expert Rev Cardiovasc Ther. 20108(10):1483-93. 12. Bursell S, Brazionis L, Jenkins A. Telehealth and Ocular Health in Diabetes. Clinical and

Experimental Optometry. 2012;95(3):311-27.

13. Noonan J, Jenkins A, Ma J-X, Keech A, Wang JJ, Lamoureux E. An Update on the Molecular Actions of Fenofibrate and its Clinical Effects on Diabetic Retinopathy and Other Microvascular Endpoints in Patients with Diabetes. Diabetes 2013;62(12):3968-75.

Book chapters

1. Polya GM, Polya Z and Jenkins AJ. Plant natural products and diabetes - biochemical

pharmacology and prospects. In Recent Progress in Medicinal Plants, Vol. II, Phytochemistry and Pharmacology (S. Singh, V.K. Singh and J.N. Govil, eds.), Research Periodicals & Book Publishing House, Houston, TX, USA. 2003.

2. Jenkins AJ, Hill MA, Rowley K. Diabetes and Oxidant Stress. In: Atherosclerosis and Oxidant

Stress. Ed. Holtzman J. 2007. (Launched American Heart Association Meeting) 3. Jenkins AJ, de Dios S, Januszewski AS. Diabetes Mellitus and Oxidative Stress. In

Cardiovascular Disease and Oxidative Stress. Novapublishers In press 2010. 4. Jenkins AJ, Klein RL, Januszewski AS. Lipoprotein Glycation. In Lipoproteins in Diabetes

Mellitus. Springer Humana Press. Eds. Jenkins, Toth and Lyons. Jan 2014 5. Peter Little, Alan Chait, Andrzej Januszewski, David O’Neal, Alicia Jenkins Emerging

Lipoprotein treatments. In Lipoproteins in Diabetes Mellitus. Springer Humana Press. Eds. Jenkins, Toth and Lyons. Jan 2014.

6. Anthony Keech, Alicia Jenkins, Val Gebski. Clinical Trials related to Lipoproteins and Diabetes. In Lipoproteins in Diabetes Mellitus. Springer Humana Press. Eds. Jenkins, Toth and Lyons. Jan 2014

Published proceedings papers

1. Requena JR, Ahmed MU, Reddy SR, Fountain CW, Degenhardt TP, Jenkins AJ, Smyth B,

Lyons TJ, Thorpe SR. Detection of AGE-lipids In Vivo: Glycation and Carboxymethylation of Aminophosholipids in Red-Cell Membranes. Proceedings of 1997 International Malliard Meeting.

2. Best JD, O’Neal D, Grieve G, Jenkins A. Atherogenic modifications of low density lipoprotein in

NIDDM. Symposium proceedings of 15th International Diabetes Federation Congress, Kobe, Japan. Excerpta Medica. S. Baba and T Kanekido, eds, pp. 436-439, 1994.

3. Januszewski AS, Thomas MC, Chung SJ, Karschimkus CS, Rowley KG, Nelson C, O'Neal D,

Wang Z, Best JD, Jenkins AJ. Plasma low-molecular weight fluorescence in type 1 diabetes mellitus. Ann N Y Acad Sci. 2005;1043:655-61.

Alicia Jenkins 58

4. Januszewski AS, Jenkins AJ, Baynes JW, Thorpe SR. Lipid-derived modifications of plasma

proteins in experimental and human diabetes. Ann N Y Acad Sci. 2005;1043:404-12. 5. Klein RL, Semler AJ, Baynes JW, Thorpe SR, Lyons TJ, Jenkins AJ. Glycation Does Not Alter

LDL-Induced Secretion of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 from Human Aortic Endothelial Cells. Ann N Y Acad Sci. 2005;1043:379-89.

Professional Journal Articles:

1. Jenkins AJ. LDL oxidizibility in diabetes. Fellowship Affairs. Royal Australasian College of Physicians. February 1997.

2. Jenkins AJ, Lyons TJ. Novel vascular disease risk factors in diabetes mellitus. Mediguide to

Endocrinology (Merck and Co., Inc.) 1:1-6, 1999.

3. Jenkins AJ. Lipoprotein binding to vascular matrix. Fellowship Affairs. Royal Australasian College of Physicians. 2001.

4. Jenkins A. The contribution of RACP funding to a research career. Fellowship Affairs. Royal

Australasian College of Physicians. May 2002.

5. Jenkins AJ. Glycoxidation and Lipoproteins in Diabetic Angiopathy. Diabetes Update. Australia. May 2002.

6. Jenkins AJ. Latest Thinking - Triglycerides and HDL. MSD Symposium Diabetic

Dyslipidaemia. Sydney, January 2005

7. D O’Neal and Jenkins AJ. Continuous glucose monitoring. Diabetes Management. 2006.

8. Jenkins AJ. Diabetes complications and genes. Diabetes Management. 2006

9. Jenkins AJ. Diabetes Care in the Future. NovoNews August 2006.

10. D O’Neal and Jenkins AJ. Insulin pump therapy in Type 1 diabetes: A brief review of the evidence. Infusystems Asia. Vol 1. No 3. 2006

11. Jenkins AJ, D O’Neal Hypoglycaemia Awareness. Diabetes Management. 2007

12. O’Neal D and Jenkins AJ. The Role of and the Principles involved in Interpreting Continuous

Glucose Monitoring Data in Implementing Changes in the Management of Diabetic Patients on Continuous Subcutaneous Insulin Infusion Therapy. InfuSystems Asia Vol 2. No 2. 2007.

13. Cross J, Jenkins AJ, Horsborough J, O’Neal DN. CSII and overseas travel. InfuSystems 2008.

(Also reprinted in the European and N. American editions).

14. Jenkins AJ and D O’Neal. Diabetic dyslipidaemia. Diabetes Management. 2008.

Alicia Jenkins 59

15. Kilmartin G, Kilmartin J, Wilkinson J, Borhra S, O’Neal, DN, Jenkins AJ. Setting up a CSII service outside a major metropolitan centre. InfuSystems Asia Vol 3 No 4. 2008.

16. Jenkins A. The contribution of RACP (Vincent Fairfax Family Foundation) funding to a

research career. Fellowship Affairs. Royal Australasian College of Physicians. 2009.

17. Jenkins A, O’Neal D. Metabolic Memory in Type 1 Diabetes. Diabetes Management June 2009

18. O’Neal D, Jenkins A. Real-time glucose monitoring – its time has almost arrived? Diabetes

Management 2009 Vol 1 No 28, p4-5.

19. Jenkins AJ, Kilmartin G, Kilmartin J, Bora S, O’Neal, DN. Upskilling Health Care Professionals in CSII. InfuSystems Asia 2010.

20. O’Neal D, Jenkins A. Real-time glucose monitoring. InfuSystems Asia and USA 2010.

21. Jenkins A, O’Neal D. The Legacy Effect in Type 2 Diabetes. Diabetes Management 2010

22. Wilkinson J, Kilmartin G, Kilmartin J, Jenkins A, O’Neal D, Eastaugh P, Bohra S. Initial

Insulin pump experience in a rural setting. InfuSystems Asia 2010.

23. Jenkins A, Jones T, O’Neal D. Recurrent Severe Hypoglycaemia Treatment Options and Pathways to RT-CGM Access in Type 1 diabetes. InfuSystems Asia. 2011

24. Seller D, O’Neal D, Hargraves M, Jenkins A. Use of Continuous Glucose Monitors in

Endurance or Safety Critical Sport. InfuSystems Asia 2012

25. A Jenkins, N Donelan, F Kirkwood, B Wainwright, R Raab. Insulin Pump Use can Facilitate Diabetes Supplies to Developing Countries. InfuSystems Asia July 2012

26. Jenkins A, O’Neal D. Dead in Bed Syndrome. InfuSystems Asia September 2012 and InfuSystems USA October 2012

27. SA McAuley, GM Ward, JC Horsburgh, AJ Jenkins, RJ MacIsaac, DN O’Neal. There Is an

Urgent Need for Evidence Upon Which to Base Clinical Decisions Advising Changes to Basal Rates in Patients Managed on Insulin Pumps. Infusystems Asia 2012

28. Jenkins A, O’Neal D. Management of Lipids in Diabetes. Endocrinology Today. Feb. 2013 29. The Australian National Adult Insulin Pump Therapy Working Group. K Alexander, W Bryant, N Cohen, M Craig, M Forbes, G Fulcher, T Greenaway, N Harrison, J Holmes-Walker, G,

Howard, J Jackson, A Jenkins, M Kamp, L Kaplan, J Kaye, A Sinha, S Stranks, D O’Neal, P Colman. Provision of Quality Care for Adults with Type 1 Diabetes Requiring Insulin Pump Therapy InfusSystems Asia April 2013 30. A Jenkins, D O’Neal. Lipid disorders in Diabetes – A common problem worth treating to target.

Endocrinology Today. April 2013

Alicia Jenkins 60

31. Jenkins A, O’Neal D. Metformin in Type 1 diabetes. Diabetes Management Vol 43, 2013 32. Jenkins A, O’Neal D. Insulin pumps for GPs in Diabetes Care. Endocrinology Today 2013. 33. O’Neal D, Blackberry I, Jenkins A, Furler J. Overcoming the delay in insulin initiation in people

with Type 2 diabetes. Diabetes Management. Vol 43, 2013 34. Seller D, Scibilia R, Rodda C, Jenkins A. Growth in insulin pump use in Australian children with

Type 1 Diabetes, and subsequent impact on a diabetes camps program. InfuSystems Asia October 2013

35. Jenkins A, O’Neal D. Episodic Use of Continuous Glucose Monitoring. InfuSystems Asia.

January 2014. 36. Jenkins AJ, O’Neal DN, Keech AC. The role of fenofibrate in the treatment of diabetic

retinopathy in Type 2 diabetes.

Editorial Duties

1. Jenkins AJ, P Toth, Lyons TJ. Lipoproteins in Diabetes. Humana Press. Contemporary Series in Diabetes. Published Jan 2014 ( 516 page hardcover book) 2. 2011 – present Editor InfuSystems Asia. A journal related to intensive diabetes control 3. 2012 - ongoing Diabetes Management.

4. 2012 – ongoing MicroRNA in Diabetes and Obesity

Lay community articles On CCRE Website: www.diabetes.ccre.unimelb.edu.au 1. Travelling with an insulin pump 2. The ALGOS Study 3. Hypoglycaemia unawareness 4. Telemedicine for Diabetes Care US Newsletters for Lay Community 4. Jenkins A. Diabetes and Bone Health. Oklahoma University Harold Hamm Oklahoma Diabetes Center. Newlsetter - First Quarter 2010. 5. Jenkins A. Similar Health Issues in Native American Indians and Indigenous Australians Indian Country Today. June 2010. ACTIVE DRUG or DEVICE TRIALS (partial list)

Investigator initiated: 2007-2010 ALGOS: An algorithm study to guide insulin pump therapy with real time glucose monitoring. Investigator (Co-PI) initiated with D O’Neal and JD Best and supported by Medtronic. (5 centres).

Alicia Jenkins 61

2010-2012. Insulin initiation in Type 2 diabetes in a GP setting with use of a masked continuous

glucose monitor. (16 centres). Supported CCRE, Sanofi-Aventis, Medtronic

Single site trial 2011 Combo-Set Trial for Medtronic re combined insulin delivery and glucose sensing line 2013-4 Orthagonal glucose sensor in Type 1 diabetes

Multi-centre trials 2001-2012 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Trial 2005-2007 Torcetrapib, a CETP inhibitor. Morbidity and Mortality End-Points Trial. Multi-center

international drug trial. (Pfizer). 2006 -2010 ASAP: Insulin pump and real time glucose sensor trial in Type 1 diabetes (Medtronic). 2007 -2008 Takeda studies 02, 07, 08, 11 2008-09 Lilly insulin trial. 2008-09 Apidra insulin pump trial. 2009-2010 Novo Premix insulin trial BOOST 2010 Sanofi-Aventis 'Landscape' insulin trial. 2014 Medtronic ComboSet Phase 1 single site trial 2011-2015 REMOVAL Study. Co-PI and Australian lead for metformin adjunct to insulin in Type 1 diabetes to retard vascular damage 2012-2014 Medtronic Next Generation (620 and 640) Insulin Pump Study 2014 Harmony Glucose sensor study (with Metronic)

ADVISORY BOARDS or ADVISORY GROUPS

2004-2012 Australian Diabetes Society Council (elected). Major roles: 2008-2012 Executive (Treasurer) 2008 – 2013 Type1 diabetes project mentor re insulin pumps and CGM and DoHA Guidelines Type 1 diabetes. 2007-09 Chair of the Education Sub-Committee responsible for approving diabetes related books, the RACGP diabetes guidelines, textbooks for schools, and pamphlets endorsed by Diabetes Australia. Member of National Association of Diabetes Centres subcommittee

Alicia Jenkins 62

Scientific Affairs Committee Medical Affairs Committee IDF liaison JDRF Australia liaison Diabetes Australia Research liaison Emergency Response re Diabetes panel ADEA education module steering committee - and presenter on CD sent to GPs. Reviewer of ADS related grant applications for research and travel awards. Member NADC committee and organizer 2007-2009 Best Practice in Diabetes Centres national conferences. Organizing committee and presenter for GP Diabetes Training Day 2011 and 2012 Organizing committee and presenter for Australia wide Endocrine Trainee Course 2010 - 2012 ADS Panel re insulin pumps and CGM support lobbying

2005-2006 Representative of Australia for DAWN Youth international advisory panel 2008-2009 Merck Diabetes 2008-2011 ADS JDRF Advisory Board to Government re insulin pump program 2009-2011 Expert Advisory Group panel for Dept. of Health and Aging Sponsored Guidelines on adult and paediatric Type 1 diabetes Care. 2009 Periodontal guidelines development panel 2006-2012 ADS Lipid Guidelines 2010 ADS Guidelines for Inpatient Glucose Managment 2011-13 Sanofi-Aventis Advisory Panel (Diabetes) 2012- JDRF Australian Clinical Research Network Panel 2011-2012 DA Position Statement on Insulin Pumps – Chair 2012 Medtronic Insulin Pumps for Type 2 Diabetes Advisory Panel 2012 RACP Telehealth Guidelines Advisory Panel 2013 DA Insulin Pump Post Marketing Review Panel COMMUNITY ACTIVITIES Diabetes Related Insulin For Life 2000-ongoing. Board member Insulin For Life, www.insulinforlife.org, a charitable organization that supplies in-date diabetes supplies to developing countries. Recipient of American Diabetes Association 2005 Harold Rifkin Award for International Service to Diabetes.

Alicia Jenkins 63

Founded and runs IFL USA (from 2005) Successful application for US$25,000 grants and partnership with Medtronic USA to expand IFL USA In 2012 Expanded IFL USA – IFL USA Florida Board Member (2012) – recipient of Helmsley Trust 1 yr grant (2013) and Diabetes Hands grant (2013). Recipient Charity of EASD Munich (2005), Copenhagen (2007), Rome (2008), Vienna (2009), Sweden (2010), Barcelona (2011), and Germany 2012 – staffs a booth, meets with recipients and donors. Partnering with Life For a Child (rolling out diabetes care to up to 26000 children and young adults with diabetes in disadvantaged countries, and with the International Diabetes Federation and NDSS. Negotiated donation of diabetes related textbook library (5 major titles) to 12 diabetes centres in 11 developing countries. Value $15,000 and Medtronic Support IFL USA Negotiated establishment of web-based data-base to record data related to the International Diabetes Federation Life For a Child Program (Graham Ogle, FRACP, Martin Silink, FRACP, PhD). This includes software donation by VELOS (usual fee US$100,000), retrospective data entry related to 700 children (data entry company paid by VELOS US$10,000), no-cost hosting of the data-base by OUHSC, Oklahoma, USA, and data-base development and data analysis by Professor Trevor Orchard (MS, FRCP, PhD) University of Pittsburgh. 2012 - ongoing Member of Medical and Scientific Advisory Board to the IDF Life For a Child program Victorian Insulin Pump Interest Group One of three endocrinologists invited to join the Victorian Insulin Pump Interest Group run by Certified Diabetes Educators. Active in preparation of guidelines launched at 2008 ADS/ADEA meeting and for national review and published as CD, paper and web format in 2009. Equal access to insulin pumps and Continuous Glucose Monitoring Member of a medical working party of doctors and Diabetes Australia staff advocating for equitable access to insulin pumps for people with Type 1 diabetes. Presentation to Health Department related to a limited access Continuous Glucose Monitoring program for Type 1 diabetes patients with recurrent severe hypoglycaemia. (Feb. 2011 – ongoing). Diabetes Support communities Invited member of D1 and Yada Yada: on-line support and activist groups of people with Type 1 diabetes and their carers. Collaborator with AcT1vate promoting exercise by people with Type 1 diabetes. Diabetes and Cardiovascular Disease Related Available as a speaker re diabetes and heart disease to lay groups and patient support groups. Previous presentations include talks to lay diabetes support groups, Rotary Clubs and Probus Club. Talks in 2009: Rotary Club (n=75 attendees), Probus Club (n=85), Bendigo Type 1 diabetes group (n=100). Talks in 2010: Six in the City (n=85 attendees), Shepparton (n=35), Melbourne (n = 200) Talks in 2011: AcT1vate GP and Type 1 diabetes patients (n=75), Melbourne.

Alicia Jenkins 64

Refugee related Free medical care to refugees Supply of in-date unopened medications for diabetes and cardiovascular care